

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(5) International Patent Classification <sup>6</sup> : <b>C07K 19/00, A61K 35/12, 35/18, 39/00, 39/385, C12N 15/62, 5/10</b>		<b>A1</b>	(11) International Publication Number: <b>WO 95/23814</b> (43) International Publication Date: <b>8 September 1995 (08.09.95)</b>
(21) International Application Number: <b>PCT/US95/02689</b> (22) International Filing Date: <b>3 March 1995 (03.03.95)</b> (30) Priority Data: <b>207,481</b> <b>4 March 1994 (04.03.94)</b> <b>US</b> (60) Parent Application or Grant (63) Related by Continuation <b>US</b> <b>08/207,481 (CIP)</b> <b>Filed on</b> <b>4 March 1994 (04.03.94)</b> (71) Applicant (for all designated States except US): <b>NATIONAL JEWISH CENTER FOR IMMUNOLOGY AND RESPIRA- TORY MEDICINE [US/US]; 1400 Jackson Street, Denver, CO 80206 (US).</b> (72) Inventors; and (75) Inventors/Applicants (for US only): <b>KAPPLER, John, W. [US/US]; 4350 Montview Boulevard, Denver, CO 80207 (US). MARRACK, Philippa [US/US]; 4350 Montview Boulevard, Denver, CO 80207 (US).</b>			(74) Agents: <b>KOVARIK, Joseph, E. et al.; Sheridan Ross &amp; McIntosh, Suite 3500, 1700 Lincoln Street, Denver, CO 80203 (US).</b> (81) Designated States: <b>AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TT, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG).</b>  <b>Published</b> <i>With international search report.</i>
(54) Title: <b>PRODUCT AND PROCESS FOR T CELL REGULATION</b>			
(57) Abstract <p>The present invention relates to a product and process for regulating the activity of T cells using major histocompatibility complexes (MHC) stably linked to antigenic peptides. Disclosed is an antigenic peptide covalently linked to a major histocompatibility complex (MHC) protein by a novel linker, thereby enabling the formation of a stable peptide-MHC complex, alone or in combination with additional MHC protein chains, capable of being recognized by a T cell receptor (TCR). Also disclosed is a nucleic molecule having a sequence encoding a Peptide-L-MHC molecule comprising an antigenic peptide joined by a linker to an MHC segment. The invention is additionally directed to formulations comprising an antigenic peptide joined by a linker to an MHC segment anchored in a lipid-containing substrate. Pharmaceutical reagents are also disclosed which contain an antigenic peptide joined by a linker to an MHC segment combined with a suitable carrier that is capable of presenting the Peptide-L-MHC molecule so that it is capable of being recognized by a T cell receptor.</p>			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

## PRODUCT AND PROCESS FOR T CELL REGULATION

Field of the Invention

The present invention relates to a product and process for regulating the activity of T cells using major  
5 histocompatibility complexes (MHC) stably linked to antigenic peptides.

Background

A wide variety of medical treatments require regulation of the immune response in a patient. Such  
10 treatments include, for example, treatments for autoimmune diseases, immunodeficiency diseases, immunoproliferative diseases, and treatments involving the transplantation of organs and skin. Traditional reagents and methods used to regulate an immune response in a patient often result in  
15 unwanted side effects. For example, immunosuppressive reagents such as cyclosporin A, azathioprine, and prednisone are used to suppress the immune system of a patient with an autoimmune disease or patients receiving transplants. Such reagents, however, suppress a patient's  
20 entire immune response, thereby crippling the ability of the patient to mount an immune response against infectious agents not involved in the original disease. Due to such harmful side effects and the medical importance of immune regulation, reagents and methods to regulate specific  
25 parts of the immune system have been the subject of study for many years.

-2-

Introduction of an antigen into a host initiates a series of events culminating in an immune response. In addition, self-host antigens can result in activation of the immune response. A major portion of the immune response is regulated by presentation of antigen by major histocompatibility complexes (MHCs). MHCs bind to peptide fragments derived from antigens to form complexes that are recognized by T cell receptors on the surface of T cells, giving rise to the phenomenon of MHC-restricted T cell recognition. The ability of a host to react to a given antigen (responsiveness) is influenced by the spectrum of MHC proteins expressed by the host. Responsiveness correlates to the ability of specific peptide fragments to bind to particular MHC proteins.

T cell receptors (TCRs) recognize antigens that are bound by MHC. Recognition of MHC complexed with peptide (MHC-peptide complex) by TCR can effect the activity of the T cell bearing the TCR. Thus, MHC-peptide complexes are important in the regulation of T cell activity and thus, in regulating an immune response.

Prior to the present invention, MHC-peptide complexes have proven to be difficult to produce and, therefore, expensive to make in large quantities. The peptides, derived synthetically or *in vivo*, did not bind to MHC in a manner that allowed for a stable and reliable complex required for medical uses. MHC-peptide complexes are currently produced by isolating MHC protein from large numbers of cells presenting membrane-bound MHC protein and

-3-

mixing in solution the isolated MHC protein with purified peptides. Separation of the MHC protein is a laborious, multi-step process and requires a large number of cells to obtain sufficient amounts of MHC protein. In addition, considerable effort is required to obtain purified peptide to mix with the MHC protein. Moreover, the association between individual peptides and MHC has been shown to be unstable.

Particular MHC-peptide complexes and methods of making them have been suggested by various investigators, including Clark et al., U.S. Patent No. 5,260,422, issued November 9, 1993; Sharma et al., U.S. Patent No. 5,194,425, issued March 16, 1993; Sharma et al., U.S. Patent No. 5,130,297, issued July 14, 1992; Nag et al., PCT Application No. WO 93/09810, published May 27, 1993; and Sanderson, U.S. Application No. 4,400,376, published Aug. 23, 1983. Prior investigators, however, have only disclosed the use of soluble, as opposed to membrane bound, MHC-peptide complexes. Moreover, methods to produce such complexes suffered from the unpredictable and unstable association of peptides with MHC.

As such, there is a need for a product and process that allows for the cost-effective production of large quantities of both soluble and membrane bound MHC-peptide complexes wherein the peptides are stably associated with the MHC proteins.

#### Summary

The present invention relates to an antigenic peptide covalently linked to a major histocompatibility complex (MHC) protein by a novel linker, thereby enabling the formation of a stable MHC-peptide complex, that is capable of being recognized by a T cell receptor (TCR), alone or in combination with additional MHC protein chains. Such stable complexes are useful for therapeutic purposes and experimental purposes.

One aspect of the present invention includes a Peptide-L-MHC molecule comprising a peptide, a linker, and an MHC segment. The peptide portion of the Peptide-L-MHC molecule is linked to the MHC segment by the linker. Also included is a method to produce Peptide-L-MHC molecule of the present invention.

One embodiment of the present invention includes a Peptide-L-MHC molecule comprising a peptide, a linker and an MHC segment comprising an MHC class I  $\alpha$  chain. In a preferred embodiment, the Peptide-L-MHC molecule further includes an MHC class I  $\beta$ 2m subunit that associates with the MHC class I  $\alpha$  chain to form a Peptide-L-MHC $_{\alpha+\beta 2m}$  composition having a functional peptide binding site.

Another embodiment of the present invention includes a Peptide-L-MHC molecule comprising a peptide, a linker and an MHC segment comprising an MHC class II  $\beta$  chain. In a preferred embodiment, the Peptide-L-MHC molecule further comprises an MHC class II  $\alpha$  chain that associates with the MHC class II  $\beta$  chain to form a Peptide-L-MHC $_{\alpha+\beta}$  composition having a functional peptide binding site.

-5-

The present invention is also directed to formulations comprising Peptide-L-MHC molecules combined with suitable carriers such that the formulations are capable of effecting an immune response. Such  
5 formulations are useful as pharmaceutical reagents for the treatment of diseases including autoimmune diseases, immunostimulatory diseases, immunoproliferation diseases and graft-host rejection. The formulations are also useful as experimental reagents. In one embodiment,  
10 compositions and molecules of the present invention are anchored to the plasma membranes of cells that are incapable of stimulating a T cell response. Cells incapable of stimulating a T cell response include red blood cells, fibroblasts, pluripotent progenitor cells,  
15 epithelial cells and neural cells.

In another embodiment, compositions and molecules of the present invention are anchored in plasma membranes of cells that are capable of stimulating a T cell response. Cells capable of stimulating a T cell response include  
20 macrophages, B cells and dendritic cells.

One embodiment of the present invention includes Peptide-L-MHC <sub>$\alpha+\beta 2m$</sub>  compositions anchored to the plasma membrane of cells that are capable of stimulating a T cell response and to cells that are incapable of stimulating an  
25 immune response. Another embodiment of the present invention includes Peptide-L-MHC <sub>$\alpha+\beta$</sub>  compositions anchored to the plasma membrane of cells that are capable of

-6-

stimulating a T cell response and to cells that are incapable of stimulating an immune response.

Another aspect of the present invention includes a nucleic acid molecule having a sequence encoding a Peptide-L-MHC molecule comprising a peptide joined by a linker to an MHC segment. The present invention also includes recombinant molecules and recombinant cells that include nucleic acid molecules of the present invention and a method to produce nucleic acid molecules of the present invention.

Another aspect of the present invention includes a method to regulate an immune response, comprising administering to an animal an effective amount of a pharmaceutical reagent comprising a compound including a Peptide-L-MHC molecule having an antigenic peptide joined by a linker to an MHC segment and/or a recombinant molecule encoding a Peptide-L-MHC molecule having an antigenic peptide joined by a linker to an MHC segment. In particular, the method comprises delivering the recombinant molecule in such a manner that the protein encoded by the recombinant molecule is expressed on the surface of cells selected from the group consisting of red blood cells, antigen presenting cells, fibroblasts, pluripotent progenitor cells, epithelial cells and neural cells, preferably red blood cells. By this method, an animal can be tolerized by the pharmaceutical reagent.

#### Brief Description of the Figures



-7-

Fig. 1 is a schematic representation of a peptide covalently associated with the binding site of an MHC protein a linker.

Fig. 2 illustrates the stabilization of soluble MHC class II molecules by covalently attached peptides.

Fig. 3 illustrates the stimulation of T cell hybridomas by purified, immobilized class II protein bound by an antigenic peptide by a linker.

Fig. 4 illustrates the expression of  $IA^b$ -Ea protein by M12.C3 cells.

Fig. 5 illustrates the inhibition by covalently associated peptide of OVA and ovalbumin to  $IA^b$ -Ea protein expressed on M12.C3 cells.

Fig. 6 illustrates stimulation of T cell hybridomas  $IA^b$ -Ea protein bearing M12.C3 cells.

Fig. 7 illustrates the expression of  $IA^b$ -Ea protein on fibroblast cells.

Fig. 8 illustrates the inhibition by covalently associated peptide of OVA binding to  $IA^b$ -Ea protein expressed on fibroblast cells.

Fig. 9 illustrates stimulation of T cell hybridomas by  $IA^b$ -Ea bearing fibroblast cells.

Fig. 10 illustrates that the  $IE^k$ -MCC transgene is expressed in bone marrow and spleen populations.

Fig. 11 illustrates that the  $IE^k$ -MCC transgene is expressed in Ter 119 antigen positive red blood cells.

-8-

Fig. 12 illustrates that the presence of the IE<sup>k</sup>-MCC transgene product decreases T cell numbers in lymph node cell populations isolated from transgenic mice.

Fig. 13 illustrates that the presence of the IE<sup>k</sup>-MCC  
5 transgene product decreases the number of IE<sup>k</sup> responsive cells in transgenic mice.

#### Detailed Description

The present invention relates to a novel product and process for regulating an immune response. The present  
10 invention includes a novel Peptide-L-MHC molecule having at least three components: (1) an antigenic peptide (Peptide) capable of effecting an immune response; (2) a linker (L); and (3) a major histocompatibility complex (MHC) segment. The peptide is linked to the MHC segment  
15 by the linker. The invention is particularly advantageous in that it provides an antigenic peptide covalently linked to an MHC protein by a linker, thereby facilitating the formation of a stable MHC-peptide complex, alone or in combination with additional MHC protein chains, that is  
20 capable of being recognized by an  $\alpha/\beta$  T cell receptor (TCR). Novel Peptide-L-MHC molecules of the present invention can form a functional peptide binding site alone or in combination with an additional MHC protein chain such that the molecule is capable of being bound by a T  
25 cell receptor. Particular embodiments of Peptide-L-MHC molecules that are capable of being bound by a T cell receptor include a Peptide-L-MHC <sub>$\alpha+\beta 2m$</sub>  composition and a

-9-

Peptide-L-MHC <sub>$\alpha\beta$</sub>  composition as described in detail below. A representation of an antigenic peptide bound to a binding site of an MHC protein and covalently associated with the MHC protein is shown in Fig. 1.

5       The major histocompatibility complex is a collection of genes encoding glycoproteins called major histocompatibility complex (MHC) proteins. *In vivo*, the primary function of an MHC protein is to present antigen in a form capable of being recognized by a TCR. An MHC  
10       protein is bound to an antigen in the form of an antigenic peptide to form an MHC-peptide complex. As used herein, "MHC-peptide complex" refers to any MHC protein having an antigenic peptide bound to one or more of the MHC protein's peptide binding sites.

15       As used herein, "TCR recognition" refers to the ability of a TCR to bind to an MHC peptide complex. The presentation of antigen by an MHC protein to the T cell normally leads to a T cell response that is clone specific. Normal T cells are distinguished from T cell  
20       hybridomas which may differ from normal T cells in their activation reactions. As used herein, "antigen presentation" refers to presenting antigen in such a manner that at least a portion of the antigen is available to be bound by a TCR. A T cell response occurs when a TCR  
25       recognizes an MHC protein bound to an antigenic peptide, thereby altering the activity of the T cell bearing the TCR. As used herein, a "T cell response" can refer to the activation, induction of anergy, or death of a T cell that

-10-

occurs when the TCR of the T cell is bound by an MHC-peptide complex. As used herein, "activation" of a T cell refers to induction of signal transduction pathways in the T cell resulting in production of cellular products (e.g., interleukin-2) by that T cell. "Anergy" refers to the diminished reactivity by a T cell to an antigen. Activation and anergy can be measured by, for example, measuring the amount of IL-2 produced by a T cell after and MHC-peptide complex has bound to the cell's TCR.

10 Anergic cells will have decreased IL-2 production when compared with stimulated T cells. Another method for measuring the diminished activity of anergic T cells includes measuring intracellular and/or extracellular calcium mobilization by a T cell upon engagement of its TCR's. As used herein, "T cell death" refers to the permanent cessation of substantially all functions of the T cell.

MHC proteins are classified in two categories: class I and class II MHC proteins. An MHC class I protein is an integral membrane protein comprising a glycoprotein heavy chain having three extracellular domains (i.e.,  $\alpha_1$ ,  $\alpha_2$  and  $\alpha_3$  and two intracellular domains (i.e., a transmembrane domain (TM) and a cytoplasmic domain (CYT)). The heavy chain is noncovalently associated with a soluble subunit called  $\beta$ 2-microglobulin ( $\beta$ 2m). An MHC class II protein is a heterodimeric integral membrane protein comprising one  $\alpha$  and one  $\beta$  chain in noncovalent association. The  $\alpha$  chain has two extracellular domains ( $\alpha_1$  and  $\alpha_2$ ), and two

-11-

intracellular domains (a TM domain and a CYT domain). The  $\beta$  chain contains two extracellular domains ( $\beta_1$  and  $\beta_2$ ), and a TM and CYT domain.

Antigenic peptides associate with an MHC protein by  
5 binding to a peptide binding site of an MHC protein. As used herein, the term "peptide binding site" refers to the portion of an MHC protein capable of binding peptide. Peptide binding sites can be internal binding sites (e.g., peptide binding grooves) or external binding sites (e.g.,  
10 binding sites on the external surface of an MHC protein). The conformation of a peptide binding site is capable of being altered upon binding of an antigenic peptide to enable proper alignment of amino acid residues important for TCR binding to the MHC protein and/or peptide.

15 The domain organization of class I and class II proteins form the peptide binding site. In one embodiment of the present invention, a peptide binding site includes a peptide binding groove. A peptide binding groove refers to a portion of an MHC protein which forms a cavity in  
20 which a peptide can bind. A peptide binding groove of a class I protein can comprise portions of the  $\alpha_1$  and  $\alpha_2$  domains. A binding groove of a class II protein can comprise portions of the  $\alpha_1$  and  $\beta_1$  domains capable of forming two  $\beta$ -pleated sheets and two  $\alpha$  helices. Without  
25 being bound by theory, it is believed that a first portion of the  $\alpha_1$  domain forms a first  $\beta$ -pleated sheet and a second portion of the  $\alpha_1$  domain forms a first  $\alpha$  helix. A first portion of the  $\beta_1$  domain forms a second  $\beta$ -pleated

-12-

sheet and a second portion of the  $\beta_1$  domain forms a second  $\alpha$  helix. The x-ray crystallographic structure of class II protein with a peptide engaged in the binding groove of the protein indicates that one or both ends of the engaged peptide can project beyond the MHC protein (Brown et al., pp. 33-39, 1993, *Nature*, Vol. 364). Thus, the ends of the  $\alpha_1$  and  $\beta_1$   $\alpha$  helices of class II apparently form an open cavity such that the ends of the peptide bound to the binding groove are not buried in the cavity. Moreover, the x-ray crystallographic structure of class II proteins indicates that the N-terminal end of the MHC  $\beta$  chain apparently projects from the side of the MHC protein in an unstructured manner since the first 4 amino acid residues of the  $\beta$  chain could not be assigned by x-ray crystallography.

In another embodiment, a peptide binding site includes an external peptide binding site in which an external surface of an MHC protein (which does not include a substantial portion of a peptide binding groove) is capable of being bound by an antigenic peptide. Such external surfaces can include any amino acid side-chain available for binding by an antigenic peptide on the external surface of the MHC protein. An external binding site on a class I protein can include the external surface of at least a portion of an  $\alpha$  chain or  $\beta_2m$  subunit. An external binding site on a class II protein can include the external surface of at least a portion of an  $\alpha$  chain or  $\beta$  chain. Preferably, the external binding site of a

-13-

class II protein includes: the  $\alpha_1$  domain or  $\alpha_2$  domain of the  $\alpha$  chain; the  $\beta_1$  domain or  $\beta_2$  domain of the  $\beta$  chain; or a combination of these domains.

In yet another embodiment, a binding site can also  
5 comprise a "combined binding site" having portions of an external binding site and portions of a binding groove which can be bound by an antigenic peptide.

One embodiment of the present invention is a Peptide-L-MHC molecule, the description of which can be best  
10 conveyed by individually discussing the various components of the novel Peptide-L-MHC. An MHC segment of the present invention can be any portion of an MHC protein that is sufficient to form, either alone or in combination with the appropriate portion of an MHC protein chain, a peptide  
15 binding site capable of presenting antigenic peptide in a manner that is able to be recognized by a TCR.

In one embodiment, an MHC segment of a Peptide-L-MHC molecule of the present invention can comprise at least a portion of a class I MHC protein, at least a portion of a  
20 class II MHC protein, or a hybrid thereof. As used herein, a "hybrid" refers to the attachment of at least a portion of a class I MHC protein to at least a portion of a class II MHC protein, to form a single MHC functional protein. According to the present invention, "at least a  
25 portion" refers to a portion of an MHC protein capable of forming a peptide binding site or capable of forming a binding site upon addition of another chain of an MHC protein. Preferred MHC segments of the present invention

-14-

include segments having at least a portion of a class I protein, and segments having at least a portion of a class II MHC protein.

One embodiment of the present invention is a soluble  
5 Peptide-L-MHC molecule. Soluble molecules of the present invention include Peptide-L-MHC molecules that are not contained in a lipid-containing substrate. A secreted Peptide-L-MHC molecule can be produced using an MHC segment that lacks sufficient amino acid sequences capable  
10 of anchoring the molecule into a lipid-containing substrate, such as an MHC transmembrane domain and/or an MHC cytoplasmic domain.

In another embodiment, a Peptide-L-MHC molecule is capable of being bound by a lipid-containing substrate,  
15 preferably by a plasma membrane of a cell that produces the Peptide-L-MHC molecule. As used herein, the term "anchored" refers to the insertion of a protein in a lipid-containing substrate such that any extracellular domains are on the outside of the substrate. A Peptide-L-  
20 MHC molecule of the present invention capable of being bound by a lipid-containing substrate is referred to herein as a membrane-bound Peptide-L-MHC molecule. An MHC segment useful in the production of a membrane-bound Peptide-L-MHC molecule can include any amino acid sequence  
25 capable of anchoring a protein into a lipid-containing substrate combined with the extracellular domains of the MHC protein. Preferably, the MHC segment contains at



-15-

least one MHC transmembrane domain and at least a portion of at least one MHC cytoplasmic domain.

In another embodiment, an MHC segment of the present invention can include at least a portion of a single chain such as a class I  $\alpha$  chain; a class II  $\alpha$  chain; a class II  $\beta$  chain; or hybrids thereof. Hybrids can include any combination of such portions, such as a single chain comprising a portion of a class I  $\alpha$  chain attached to a portion of a class II  $\beta$  chain. Peptide-L-MHC molecules containing such MHC segments can be combined with an appropriate distinct MHC protein chain capable of associating with the Peptide-L-MHC molecule to form a complex having a function peptide binding site.

A preferred class I  $\alpha$  chain of the present invention contains class I  $\alpha_1$ ,  $\alpha_2$  and  $\alpha_3$  domains. A preferred class II  $\alpha$  chain of the present invention contains class II  $\alpha_1$  and  $\alpha_2$  domains. A preferred class II  $\beta$  chain contains  $\beta_1$  and  $\beta_2$  domains. A preferred hybrid MHC segment of the present invention includes at least portions of a class I  $\alpha$  chain and a class II  $\beta$  chain.

Preferred embodiments of an MHC segment of the present invention include segment having a class II  $\beta$  chain which includes a  $\beta_1$  domain, a  $\beta_2$  domain, and a segment having a class II  $\beta$  chain which includes a  $\beta_1$  domain, a  $\beta_2$  domain, a  $\beta$  chain transmembrane domain and a  $\beta$  chain cytoplasmic domain.

An antigenic peptide of the present invention can comprise any peptide that is capable of binding to an MHC

-16-

protein in a manner such that the MHC-peptide complex can bind to TCR and effect a T cell response. A peptide of the present invention can be synthesized by a cell, externally or internally hydrolyzed, or a post-translation  
5 modification product.

Examples of antigenic peptides can be include: an antigenic peptide synthesized inside of a cell; an antigenic peptide synthesized outside of a cell; an antigenic peptide hydrolyzed inside of a cell; or an  
10 antigenic peptide hydrolyzed outside of a cell. Such examples include antigenic peptides derived from exogenous antigens which enter a cell and exogenous antigens which remain outside of a cell.

Antigenic peptides that are produced by hydrolysis of  
15 antigens undergo hydrolysis prior to binding of the antigen to an MHC protein. Class I MHC proteins typically present antigenic peptides derived from proteins actively synthesized by a cell. In contrast, class II MHC proteins typically present antigenic peptides derived from  
20 exogenous protein that enter a cell's endocytic pathway. Intracellular trafficking permits an antigenic peptide to become associated with an MHC protein. The resulting MHC-peptide complex then travels to the surface of the cell where it is available for interaction with a TCR.

25 In one embodiment, an externally derived antigenic peptide can become associated with unoccupied MHC proteins on the surface of cell. Such antigenic peptides can be generated by, for example, proteolytic digestion of

-17-

proteins in extracellular fluids such as serum. The MHC-peptide complex can then be presented to a TCR. In another embodiment, antigenic peptides that are not hydrolyzed can associate with unoccupied MHC proteins on the surface of a T cell and can be presented to a TCR.

Another embodiment of the present invention is a groove-binding antigenic peptide, which is an antigenic peptide that is capable of binding to a peptide binding groove of an MHC protein in such a manner that the resulting Peptide-MHC complex can bind to a TCR. It is believed that the binding of an antigenic peptide to an MHC peptide binding groove can control the spatial arrangement of MHC and/or antigenic peptide amino acid residues recognized by a TCR. Such spatial control may be due in part to hydrogen bonds formed between a peptide and an MHC protein. Preferably, the length of a groove-binding antigenic peptide extends from about 5 to about 40 amino acid residues, more preferably from about 6 to about 30 amino acid residues, and even more preferably from about 8 to about 20 amino acid residues.

Preferred groove-binding antigenic peptides include those that bind to MHC protein involved in autoimmune diseases, immunodeficiency diseases, immunoproliferation diseases, and graft-host rejection. More preferred groove specific peptides of the present invention include Arg-Ala-Asp-Leu-Ile-Ala-Tyr-Leu-Lys-Gln-Ala-Thr-Lys, Val-His-Ala-Ala-His-Ala-Glu-Ile-Asn-Glu-Ala-Gly-Arg, Arg-Ala-Asp-Leu-Ile-Ala-Tyr-Leu-Lys-Gln-Ala-Thr-Lys, Val-His-Ala-Ala-

-18-

His-Ala-Glu-Ile-Asn-Glu-Ala-Gly-Arg and Ala-Ser-Phe-Glu-Ala-Gln-Gly-Ala-Leu-Ala-Asn-Iso-Ala-Val-Asp-Lys-Ala, and functional equivalents thereof.

As stated above, antigenic peptides useful in the present invention can either bind to a binding groove, to an external binding site, or to a combined binding site. External antigenic peptides of the present invention can bind to both a TCR and an MHC protein in such a manner that a T cell response occurs. Peptides useful in the present invention include superantigens, a family of T cell stimulatory proteins that are capable of binding MHC protein and TCR to induce a T cell response. A superantigen is believed to bind to at least a portion of the  $\alpha$  chain of class II, the  $\beta$  chain of class II, or a combination of the  $\alpha$  and  $\beta$  chains of class II. Superantigens are also believed to bind to at least a portion of a  $V_{\beta}$  domain of a TCR.

Preferred external peptides of the present invention include polypeptides having a molecular weight of at least about 5 kD, more preferably at least about 15 kD, and even more preferably at least about 20 kD. Suitable antigenic peptides of the present invention include peptides comprising at least a portion of an antigen selected from a group consisting of autoantigens, infectious agents, toxins, allergens, or mixtures thereof. Preferred autoantigens of the present invention include, but are not limited to, antigens which result in the development of systemic lupus, rheumatoid arthritis, myasthenia gravis,

-19-

multiple sclerosis, and insulin dependent diabetes mellitus.

Preferred infectious agents of the present invention include, but are not limited to, bacteria, viruses, and  
5 eukaryotic parasites. Preferred animal parasites include protozoan parasites, helminth parasites (such as nematodes, cestodes, trematodes, ectoparasites and fungi.

Preferred allergens of the present invention include, but are not limited to plant, animal, bacterial, parasitic  
10 allergens and metal-based allergens that cause contact sensitivity. More preferred allergens include weed, grass, tree, peanut, mite, flea, and cat antigens.

Preferred toxins of the present invention include, but are not limited to, staphylococcal enterotoxins, toxic  
15 shock syndrome toxin, retroviral antigens, streptococcal antigens, mycoplasma, mycobacterium, and herpes viruses. Retroviral antigens include antigens derived from human immunodeficiency virus. Even more preferred toxins include SEA, SEB, SE<sub>1,3</sub>, SED, and SEE.

20 A Peptide-L-MHC molecule of the present invention contains a novel linker which comprises an amino acid sequence that covalently associates an MHC segment with an antigenic peptide. Covalent bonds are formed between the antigenic peptide and the linker, and between the linker  
25 and the MHC segment. The linker is distinguished from a peptide linkage which refers to the chemical interaction between two amino acids.

-20-

Prior to the development of novel Peptide-L-MHC molecules of the present invention, MHC-peptide complexes suffered from unpredictable and unstable association of peptides with MHC proteins. In their native state, antigenic peptides associate with MHC proteins in a noncovalent manner resulting in an inherently unstable MHC-peptide complex. In addition, MHC-peptide complexes derived from mixing antigenic peptides and MHC proteins *in vitro* suffer even greater instability problems because the formation and stability of the complexes can be affected by the equilibrium between the complex and non-complexed peptides. The instability of both native and man-made MHC-peptide complexes limits the use of the complexes as reliable reagents for medical and/or experimental use.

The novel linker of the present invention alleviates such problems and allows for the production of MHC-peptide complexes that are uniquely suitable for use as therapeutic and experimental agents. The ability to attach an antigenic peptide to an MHC segment via a linker to produce a functional MHC-peptide complex is unexpected because the association of antigenic peptide with the MHC peptide binding site is considered to be a tight and carefully defined fit. As such, a skilled artisan would predict that a linker would hinder the ability of an antigenic peptide to bind to an MHC peptide binding site by, for example, steric hindrance due to the size or location of a linker relative to an antigenic peptide and a peptide binding site, or to amino acid charge

-21-

interactions between a linker and an MHC protein. A skilled artisan would also predict that a linker would hinder the interaction of an MHC protein bound by antigenic peptide with a TCR by steric hindrance and/or amino acid charge interactions. Despite such prevalent beliefs in the field, the present inventors have identified and produced linkers that do not substantially hinder the association of an antigenic peptide with an MHC binding site and, moreover, stabilize the association of the peptide with the MHC.

A linker useful in the production of a Peptide-L-MHC molecule can comprise any amino acid sequence that facilitates the binding of an antigenic peptide to an MHC protein. A linker can facilitate antigenic peptide binding by, for example, maintaining an antigenic peptide within a certain distance of an MHC peptide binding site to promote efficient binding. The linker enhances the ability of a combined aggregate of antigenic peptide and MHC protein to act as a unit in triggering a desired immune response. Preferably, a linker of the present invention is capable of facilitating the binding of the antigenic peptide portion of a Peptide-L-MHC molecule to the MHC protein segment of either a Peptide-L-MHC $_{\alpha+\beta}$  composition or a Peptide-L-MHC $_{\alpha+\beta 2m}$  composition (as defined in detail below) that is capable of being recognized by a TCR.

According to the present invention, a linker of the present invention stabilizes the association of an

-22-

antigenic peptide with an MHC peptide binding site, resulting in the formation of a stable composition that can be recognized by a TCR. As used herein, the term "stability" refers to the maintenance of the association

5 of a peptide with an MHC peptide binding site in the presence of forces that typically cause the dissociation of complexed peptide and MHC protein. The stability of a peptide bound to an MHC peptide binding site can be measured in a variety of ways known to those skilled in

10 the art. For example, an MHC-peptide complex can be passed over an high pressure liquid chromatography (HPLC) sizing column and analyzed for maintenance of the complex. In addition, MHC-peptide complexes can be incubated in increasing concentrations of sodium dodecyl sulfate (SDS)

15 for an appropriate amount of time, at an appropriate temperature, and analyzed for maintenance of the complex. Suitable concentrations of SDS include from about .01% SDS to about 5% SDS. The stability of Peptide-L-MHC molecules (including, but not limited to Peptide-L-MHC <sub>$\alpha+\beta 2m$</sub>

20 compositions, or Peptide-L-MHC <sub>$\alpha+\beta$</sub>  compositions) preferably is substantially the same as or greater than the stability of a native form of the complex. Preferably, the stability of such molecules and compositions are measured by passage of such proteins over HPLC sizing columns and

25 comparing the peak location of eluant proteins with comparable native protein (i.e., peptide bound MHC protein that does not possess a linker) passed over the same or a substantially similar column.



-23-

A linker useful in the production of a Peptide-L-MHC molecule can comprise any amino acid sequence that does not substantially hinder interaction of an antigenic peptide with an MHC protein or hinder interaction of an MHC protein bound by peptide with a TCR.

The length of a linker of the present invention is preferably sufficiently short (i.e., small enough in size) such that the linker does not substantially inhibit binding between the antigenic peptide and the MHC segment of a Peptide-L-MHC molecule or inhibit TCR recognition. Preferably, the length of a linker of the present invention is from about 1 amino acid residue to about 40 amino acid residues, more preferably from about 5 amino acid residues to about 30 amino acid residues, and even more preferably from about 8 amino acid residues to about 20 amino acid residues.

In addition, the amino acid composition of a linker of the present invention is substantially neutral such that the linker does not inhibit MHC-peptide complex formation or TCR recognition by the complex. As used herein, the term "neutral" refers to amino acid residues sufficiently uncharged or small in size so that they do not prevent interaction of a linker with an MHC segment. Preferred amino acid residues for linkers of the present invention include, but are not limited to glycine, alanine, leucine, serine, valine, threonine, and proline residues. More preferred linker amino acid residues include glycine, serine, leucine, valine, and proline

-24-

residues. Linker compositions can also be interspersed with additional amino acid residues, such as arginine residues. Linker amino acid residues of the present invention can occur in any sequential order such that  
5 there is no interference with binding of an antigenic peptide to an MHC protein or of the resulting MHC-peptide complex with a TCR. Linkers having the amino acid sequence Gly-Gly-Gly-Gly-Ser-Leu-Val-Pro-Arg-Gly-Ser-Gly-Gly-Gly-Gly-Ser and Gly-Gly-Gly-Gly-Ser-Gly-Gly-Gly-Gly-Ser  
10 Ser are particularly preferred.

One embodiment of the present invention relates to a linker having an amino acid sequence that contains a target site for an enzyme capable of cleaving proteins. Such linkers are hereinafter referred to as "processable  
15 linkers". Processable linkers can be designed to inhibit TCR recognition of a Peptide-L-MHC molecule until such Peptide-L-MHC molecule reaches a targeted site of action (i.e., a site of inflammation). At the site of action, the processable linker could be cleaved by an enzyme  
20 present at the site, thereby transforming the inactive Peptide-L-MHC molecule into an active form capable of being recognized by a TCR. The Peptide-L-MHC could be inactive prior to cleavage due to an antigenic peptide being unable to bind to an MHC protein or due to the  
25 inability of a TCR to recognize the MHC protein bound by the antigenic peptide. Charge and/or steric hindrance can be eliminated once the linker is cleared, thereby allowing the MHC-peptide complex to be recognized by a

-25-

TCR. A processable linker can further comprise an immunogenic sequence representing a foreign determinant that can be removed by cleaving serum enzyme target sites also contained on the linker.

5 Preferred processable linkers of the present invention include linkers containing target sites for enzymes such as collagenases, metalloproteases, serine proteases, cysteine proteases, kallikriens, thrombin, and plasminogen activators. A preferred processable linker of  
10 the present invention includes a linker having a thrombin cleavage site of Leu-Val-Pro-Arg-Gly-Ser.

Suitable linkers useful in the present invention can be designed using various methods. For example, x-ray crystallographic data of an MHC protein can be used to  
15 design a linker of suitable length and charge such that the linker does not interfere with TCR recognition of the MHC-peptide complex. Suitable linkers can also be identified by producing large numbers of different Peptide-L-MHC molecules having different combinations of  
20 antigenic peptides, linkers and MHC segments and determining if those molecules, alone or in combination with other distinct MHC protein chains, can be recognized by a TCR. In addition, linkers known to function well with one particular Peptide-L-MHC molecule can be combined with  
25 other antigenic peptide and MHC segment combinations, and tested for the ability of the resulting Peptide-L-MHC molecule to affect a T cell response, either alone or in combination with other MHC protein chains.

-26-

A Peptide-L-MHC molecule of the present invention can, either alone or in combination with another MHC protein chain, form a peptide binding site. A Peptide-L-MHC molecule of the present invention can be combined with  
5 a distinct MHC protein chain, thereby forming a composition having a peptide binding site. Such a composition is capable of being recognized by a TCR. In one embodiment of the present invention, a Peptide-L-MHC molecule having an MHC segment comprising an MHC class I  
10  $\alpha$  chain is associated with at least a portion of a class I  $\beta$ 2m subunit to form a Peptide-L-MHC <sub>$\alpha$ + $\beta$ 2m</sub> composition having a functional peptide binding site. Association between the Peptide-L-MHC molecule and the  $\beta$ 2m subunit can be covalent or noncovalent.

15 In another embodiment, a Peptide-L-MHC molecule of the present invention having an MHC segment comprising an MHC class II  $\beta$  chain is associated with at least a portion of an MHC class II  $\alpha$  chain to form a Peptide-L-MHC <sub>$\alpha$ + $\beta$</sub>  composition having a functional peptide binding site.  
20 Association between the Peptide-L-MHC molecule and the class II  $\beta$  chain can be covalent or noncovalent.

In a further embodiment, a Peptide-L-MHC molecule of the present invention can include an effector component, such as a label or a toxin. The effector component can be  
25 conjugated either to the MHC segment or to the peptide of a Peptide-L-MHC molecule. Suitable toxins include, but are not limited to: double chain toxins (i.e., toxins having A and B chains), such as diphtheria toxin, ricin

-27-

toxin, *Pseudomonas* exotoxin, modeccin toxin, abrin toxin, and shiga toxin; single-chain toxins, such as pokeweed antiviral protein, alpha-amanitin, and ribosome inhibiting proteins; and chemical toxins, such as melphalan, methotrexate, nitrogen mustard, doxorubicin and daunomycin. Suitable labels include, but are not limited to fluorescent labels, biotin, at least a portion of an immunoglobulin protein, metallic compounds, luciferin, radiolabels and enzymes.

Another aspect of the present invention relates to a nucleic acid molecule that encodes a protein of the present invention comprising the Peptide-L-MHC molecules disclosed herein. According to the present invention, references to nucleic acids also refer to nucleic acid molecules. A nucleic acid molecule can be DNA, RNA, or hybrids or derivatives of either DNA or RNA. Nucleic acid molecules of the present invention can include regulatory regions that control expression of the nucleic acid molecule (e.g., transcription or translation control regions), full-length or partial coding regions, and combinations thereof. Any portion of a nucleic acid molecule of the present invention can be produced by: (1) isolating the molecule from its natural milieu; (2) using recombinant DNA technology (e.g., PCR amplification, cloning); or (3) using chemical synthesis methods. A nucleic acid of the present invention can include functional equivalents of natural nucleic acid molecules encoding an MHC segment or a peptide, including, but not

-28-

limited to, natural allelic variants and modified nucleic acid molecules in which nucleotides have been inserted, deleted, substituted, and/or inverted in such a manner that such modifications do not substantially interfere with the nucleic acid molecule's ability to encode a protein of the present invention capable of forming compositions that can be recognized by T cell receptors. Preferred functional equivalents include sequences capable of hybridizing under stringent conditions, to at least a portion of a Peptide-L-MHC molecule encoding nucleic acid molecule (according to conditions described in Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Labs Press, 1989, which is incorporated herein by reference in its entirety). As guidance in determining what particular modifications can be made to any particular nucleic acid molecule, one of skill in the art should consider several factors that, without the need for undue experimentation, permit a skilled artisan to appreciate workable embodiments of the present invention. For example, such factors include modifications to nucleic acid molecules done in a manner so as to maintain particular functional regions of the encoded proteins including, a working peptide binding domain, a TCR binding domain and a linker that does not substantially interfere with desired binding interactions. Functional tests for these various characteristics (e.g., binding studies) allows one of skill in the art to determine what

-29-

modifications to nucleic acid sequences would be appropriate and which would not.

One embodiment of the present invention includes a nucleic acid molecule encoding a Peptide-L-MHC molecule having at least three components: (1) an MHC segment; (2) a peptide; and (3) a linker. Suitable and preferred segments, peptides and linkers for use in the present invention are heretofore disclosed. A nucleic acid molecule of the present invention comprises at least one nucleic acid sequence encoding an MHC segment, covalently attached (by base pair linkage) to at least one nucleic acid sequence encoding a linker, which is itself covalently attached (by base pair linkage) to at least one nucleic acid sequence encoding an antigenic peptide. The nucleic acid sequences are attached in such a manner that the sequences are transcribed in-frame, thereby producing a functional Peptide-L-MHC molecule capable of forming a peptide binding site, alone or in combination with another MHC protein chain.

Preferred nucleic acid molecules encoding Peptide-L-MHC molecules include: nucleic acid sequences encoding an MHC class I  $\alpha$  chain, a linker and an antigenic peptide, wherein the peptide is linked to the class I  $\alpha$  chain by the linker; and an MHC class II  $\beta$  chain, a linker and an antigenic peptide, wherein the peptide is linked to the class II  $\beta$  chain by the linker. Particularly preferred nucleic acid molecules encode  $IE\beta^k$  or a functional equivalent thereof;  $IA\beta^d$  or a functional equivalent

-30-

thereof; and  $IA\beta^b$  or a functional equivalent thereof. A portion of each nucleic acid molecule encoding a component (i.e., an MHC segment, a linker, or an antigenic peptide) of a Peptide-L-MHC molecule can be covalently associated (using standard recombinant DNA methods) to any other sequence encoding at least a portion of a distinct component to produce a Peptide-L-MHC molecule of the present invention. A nucleic acid sequence encoding a linker is preferably covalently associated (by base pair linkage, e.g., ligated) to a nucleic acid sequence encoding an MHC segment and encoding a linker. In one embodiment, the 3' end (end encoding the C-terminus) of a nucleic acid molecule encoding an antigenic peptide of the present invention is ligated to the 5' end (end encoding the N-terminus) of a nucleic acid molecule encoding a linker of the present invention and the 3' end of the nucleic acid sequence encoding the linker is ligated to the 5' end of a nucleic acid molecule encoding an MHC segment. Particular embodiments of nucleic acid molecules encoding Peptide-L-MHC of the present invention are shown in Tables 2-6. The construction of such molecules is described in detail in the Examples. Also shown in Fig. 1 are restriction enzyme sites and sequences that regulate transcription.

In another embodiment, nucleic acid molecules of the present invention include a nucleic acid molecule encoding a Peptide-L-MHC $_{\alpha+\beta}$  composition, wherein the sequence encoding the MHC class II  $\alpha$  chain can be on the same or on



-31-

a separate nucleic acid molecule as the sequence encoding an MHC class II  $\beta$  chain. For example, a nucleic acid molecule encoding a Peptide-L-MHC $_{\alpha,\beta}$  composition can contain: a sequence encoding a MHC class I MHC $_{\alpha}$ -L-Peptide molecule ligated to a sequence encoding a  $\beta 2m$  subunit; a  
5 sequence encoding an MHC class II MHC $_{\beta}$ -L-Peptide molecule ligated to a sequence encoding an MHC class II  $\alpha$  chain encoding sequence; or a sequence encoding an MHC class II MHC $_{\alpha}$ -L-Peptide molecule ligated to a sequence encoding an  
10 MHC class II  $\beta$  chain encoding sequence.

In other embodiments, a nucleic acid sequence is used that encodes for a signal or leader segment that is capable of promoting secretion of a Peptide-L-MHC molecule from the cell that produces the molecule. Nucleic acid  
15 sequences encoding the leader or signal segments are covalently associated (by base pair linkage) to the 5' end of a nucleic acid molecule. The leader or signal segments can be segments which naturally are associated with an MHC segment or are heterologous. Preferred segments are  
20 naturally associated segments. To obtain membrane-bound embodiments, nucleic acid sequences are used that contain at least one transmembrane segment capable of anchoring a Peptide-L-MHC molecule to a lipid-containing substrate, such segments including at least a portion of an MHC  
25 transmembrane domain and at least a portion of an MHC cytoplasmic domain. A nucleic acid sequence encoding a transmembrane segment is covalently associated (by base pair linkage) to the 3' end of a nucleic acid sequence

-32-

encoding the extracellular portion of a Peptide-L-MHC molecule. The transmembrane segment can be a segment naturally associated with the MHC segment or heterologous. Preferred transmembrane segments include segments that are naturally associated with an MHC segment. A nucleic acid molecule encoding a Peptide-L-MHC capable of being membrane-bound contains at least one nucleic acid sequence encoding a segment ligated to the 3' end of an extracellular domain in a manner such that the transmembrane encoding sequence is transcribed in-frame.

Another embodiment of the present invention is a fusion protein that includes a Peptide-L-MHC molecule containing-domain attached to a fusion segment. Inclusion of a fusion segment as part of a Peptide-L-MHC molecule of the present invention can enhance the molecule's stability during production, storage and/or use. Furthermore, a fusion segment can function as a tool to simplify purification of a Peptide-L-MHC molecule, such as to enable purification of the resultant fusion protein using affinity chromatography. A suitable fusion segment can be a domain of any size that has the desired function (e.g., increased stability and/or purification tool). It is within the scope of the present invention to use one or more fusion segments. Fusion segments can be joined to amino and/or carboxyl termini of the Peptide-L-MHC molecule. Linkages between fusion segments and Peptide-L-MHC molecule can be made to be susceptible to cleavage to enable straight-forward recovery of the Peptide-L-MHC

-33-

molecules. Fusion proteins are preferably produced by culturing a recombinant cell transformed with a fusion nucleic acid sequence that encodes a protein including the fusion segment attached to either the carboxyl and/or amino terminal end of a Peptide-L-MHC molecule.

Particularly preferred nucleic acid molecules include: N-IE<sup>kd</sup>-MCC having sequences encoding a moth cytochrome C (91-103) peptide, a linker and an IE $\beta^k$  protein (described in detail in Example 1); N-IA<sup>d</sup>-OVA having sequences encoding the cOVA (327-339) peptide, a linker and an IA $\beta^d$  protein (described in detail in Example 1); and N-IA<sup>b</sup>-Ea having sequences encoding an IE $\alpha^d$  (56-73) peptide, a linker and an IA $\beta^b$  protein (described in detail in Example 2).

The present invention also includes a recombinant molecule comprising a nucleic acid sequence encoding a Peptide-L-MHC molecule operatively linked to a vector capable of being expressed in a host cell. As used herein, "operatively linked" refers to insertion of a nucleic acid sequence into an expression vector in such a manner that the sequence is capable of being expressed when transformed into a host cell. As used herein, an "expression vector" is an RNA or DNA vector capable of transforming a host cell and effecting expression of an appropriate nucleic acid sequence, preferably replicating within the host cell. An expression vector can be either prokaryotic or eukaryotic, and typically is a virus or a plasmid.

-34-

Recombinant molecules of the present invention include pIE<sup>kd</sup>-MCC (described in detail in Example 1); pIA<sup>d</sup>-OVA (described in detail in Example 1); pM12-IA<sup>b</sup>-EA (described in detail in Example 2); and pFIB-IA<sup>b</sup>-Ea  
5 (described in detail in Example 2).

Construction of desired expression vectors can be performed by methods known to those skilled in the art and expression can be in eukaryotic or prokaryotic systems. Prokaryotic systems typically used are bacterial strains  
10 including, but not limited to various strains of *E. coli*, various strains of *bacilli* or various species of *Pseudomonas*. In prokaryotic systems, plasmids are used that contain replication sites and control sequences derived from a species compatible with a host cell.  
15 Control sequences can include, but are not limited to promoters, operators, enhancers, ribosome binding sites, and Shine-Dalgarno sequences. Expression systems useful in eukaryotic host cells comprise promoters derived from appropriate eukaryotic genes. Useful mammalian promoters  
20 include early and late promoters from SV40 or other viral promoters such as those derived from baculovirus, polyoma virus, adenovirus, bovine papilloma virus or avian sarcoma virus. Expression vectors of the present invention include any vectors that function (i.e., direct gene  
25 expression) in recombinant cells of the present invention including bacterial, yeast, other fungal, insect, and mammalian cells. Particularly preferred expression vectors of the present invention include dual promoter

-35-

baculovirus transfer vectors, and vectors containing class II promoters,  $\beta$ -actin promoters, globin promoters, or epithelial cell specific promoters.

5 An expression system can be constructed from any of the foregoing control elements operatively linked to the nucleic acid sequences of the present invention using methods known to those of skill in the art. (see, for example, Sambrook et al., *ibid.*)

Host cells of the present invention can be: cells  
10 naturally capable of producing MHC protein; or cells that are capable of producing MHC protein when transfected with a nucleic acid molecule encoding an MHC protein. Host cells of the present invention include, but are not limited to bacterial, fungal, insect and mammalian cells.  
15 Suitable host cells include mammalian cells capable of stimulating a T cell response, preferably antigen presenting cells including dendritic cells, macrophages and B lymphocytes, as well as cells that are not capable of stimulating a T cell response, preferably fibroblasts,  
20 red blood cells, pluripotent progenitor cells, epithelial cells and neural cells.

One particular embodiment involves a host cell transformed with a recombinant molecule encoding a Peptide-L-MHC molecule, wherein the MHC segment of the  
25 molecule is a class II  $\beta$  chain. The host cell can also be co-transformed with a recombinant molecule encoding an MHC class II  $\alpha$  chain capable of associating with the Peptide-L-MHC molecule to form a Peptide-L-MHC $_{\alpha+\beta}$  composition.

-36-

In one aspect of the present invention, recombinant cells can be used to produce at least one Peptide-L-MHC molecule by culturing such cells under conditions effective to produce such molecules, and recovering the molecules. Effective conditions to produce a recombinant molecule include, but are not limited to appropriate culture media, bioreactor, temperature, pH and oxygen conditions. Depending on the expression vector used for production, resultant molecules can either remain within the recombinant cell, be retained on the outer surface of the recombinant cell, or be secreted into the culture medium. As used herein, the term "recovering the protein" refers to collecting the fermentation medium containing the protein and/or recombinant cells. Recovery need not imply additional steps of separation or purification. Peptide-L-MHC molecules of the present invention can be purified using a variety of standard protein purification techniques such as, but not limited to affinity chromatography, ion exchange chromatography, filtration, centrifugation, electrophoresis, hydrophobic interaction chromatography, gel filtration chromatography, chromatofocusing and differential solubilization. Isolated Peptide-L-MHC molecules are preferably retrieved in "substantially pure" form. As used herein, "substantially pure" refers to a purity that allows for the effective use of the molecule as a heretofore described pharmaceutical composition or experimental reagent.

-37-

Soluble Peptide-L-MHC molecules of the present invention can be purified using, for example, immunoaffinity chromatography. Peptide-L-MHC molecules anchored in a lipid-containing substrate can be recovered  
5 by, for example, density gradient centrifugation techniques.

One aspect of the present invention relates to the use of Peptide-L-MHC molecules and nucleic acid molecules of the present invention as formulations for therapeutic  
10 or experimental use. In one embodiment, a Peptide-L-MHC molecule of the present invention can be used to produce a protein pharmaceutical reagent. Such protein pharmaceutical reagents are useful for administration to patients suffering from diseases such as autoimmune  
15 diseases, immunodeficiency diseases, and immunoproliferative diseases, or from graft-host rejection. A protein pharmaceutical reagent includes a Peptide-L-MHC molecule associated with a suitable carrier. A Peptide-L-MHC molecule of the present invention can also  
20 be used to produce a protein experimental reagent. A protein experimental reagent is a reagent useful for the development of drugs and for the study of different aspects of an immune response. A protein experimental reagent includes a Peptide-L-MHC molecule associated with  
25 a suitable pharmaceutically acceptable carrier. "Pharmaceutically acceptable" refers to a compound that is not harmful (e.g., toxic) to a cell or an animal.

-38-

As used herein, a "carrier" refers to any substance suitable as a vehicle for delivering a molecule or composition to a suitable *in vitro* or *in vivo* site of action. As such, carriers can act as an excipient for formulation of a protein pharmaceutical or experimental reagent containing a Peptide-L-MHC molecule. Preferred carriers are capable of maintaining Peptide-L-MHC molecules in a form that is capable of being recognized by a T cell receptor. Examples of such carriers include, but are not limited to water, phosphate buffered saline, Ringer's solution, dextrose solution, serum-containing solutions, Hank's solution and other aqueous physiologically balanced solutions. Aqueous carriers can also contain suitable auxiliary substances required to approximate the physiological conditions of the recipient, for example, enhancement of chemical stability and isotonicity. Suitable auxiliary substances include, for example, sodium acetate, sodium chloride, sodium lactate, potassium chloride, calcium chloride, sorbitan monolaurate, triethanolamine oleate, and other substances used to produce phosphate buffer, Tris buffer, and bicarbonate buffer. Auxiliary substances can also include preservatives, such as thimerosal, m or o-cresol, formalin and benzyl alcohol. Preferred auxiliary substances for aerosol delivery include surfactant substances nontoxic to a recipient, for example, esters or partial esters of fatty acids containing from about 6 to about 22 carbon atoms. Examples of esters include, caproic, octanoic,



lauric, palmitic, stearic, linoleic, linolenic, olesteric, and oleic acids. Formulations of the present invention can be sterilized by conventional methods and/or lyophilized.

5 Carriers of the present invention can also include adjuvants including, but not limited to, Freund's adjuvant; other bacterial cell wall components; aluminum-based salts; calcium-based salts; silica; polynucleotides; toxoids; serum proteins; viral coat proteins; and other  
10 bacterial-derived preparations.

Useful carriers for membrane-bound Peptide-L-MHC molecules include any artificial or natural lipid-containing substrate, preferably cells, cellular membranes, liposomes and micelles. Cellular carriers of  
15 the present invention include cells essentially incapable of stimulating T cells, such as cells that lack secondary proteins capable of mediating T cell activation, as well as cells that stimulate T cells and that have secondary proteins that mediate T cell activity. Preferred  
20 mammalian cells of the present invention include, but are not limited to antigen presenting cells, fibroblasts, red blood cells, pluripotent progenitor cells, epithelial cells, and neural cells. Antigen presenting cells are cells that typically express MHC proteins on their cell  
25 surface and that are capable of processing antigens. Preferred antigen presenting cells include, for example, dendritic cells, macrophages and B lymphocytes.

-40-

In one embodiment of the present invention, a membrane-bound Peptide-L-MHC molecule is attached to artificial and/or natural lipid-containing carriers to produce formulations capable of suppressing T cell activity. Without being bound by theory, it is believed that T cells require distinct signals for activation. One such signal is delivered through a TCR, following the receptor's binding with peptide presented in the context of MHC protein such as to a Peptide-L-MHC of the present invention. It is, however, believed that signalling through the TCR alone is insufficient to optimally activate a T cell. As such, the absence of a second signal from a surface protein other than the TCR can result in T cell suppression which herein refers to one of the following: (1) failure to activate the T cell; (2) induction of a T cell into an anergic state; or (3) killing of the T cell. A variety of non-TCR proteins on the surface of a T cell can, in conjunction with Peptide-L-MHC molecule binding to TCR, mediate signal transduction resulting in T cell activation. An example of a non-TCR signal transduction protein is the T cell protein CD28. CD28 is believed to co-stimulate a T cell with TCR, resulting in T cell activation. CD28 is the receptor for the protein B7 which is found on antigen presenting cells. As such, it is believed that binding to TCR by an MHC-peptide complex and to CD28 by a B7 protein can result in T cell activation. Conversely, the absence of CD28

-41-

binding to B7 in the presence of TCR binding by a peptide-MHC complex, does not result in activation of a T cell.

Preferred lipid-containing carriers for protein formulations capable of suppressing T cell activity include, for example micelles, liposomes, cells and cellular membranes essentially incapable of stimulating a T cell response. More preferred carriers include mammalian cells, such as red blood cells, fibroblast cells, pluripotent progenitor cells, epithelial cells and neural cells.

In another embodiment, a membrane-bound Peptide-L-MHC molecule is used to produce protein formulations capable of stimulating T cell activity. As used herein, T cell stimulation refers to the activation of a T cell resulting in biological function, such as IL-2 production or cytotoxic activity. Preferably, lipid-containing carriers, such as micelles, liposomes, cells and cellular membranes essentially capable of stimulating a T cell response, are used to produce formulations that are capable of stimulating T cell activity. More preferred carriers include mammalian antigen presenting cells, such as dendritic cells, macrophages and B lymphocytes.

In yet another embodiment, a soluble Peptide-L-MHC molecule is used to produce protein formulations capable of suppressing T cell activity. Preferred carriers for soluble Peptide-L-MHC molecules include physiologically balanced solutions, and a more preferred carrier is phosphate buffered saline.

-42-

In one embodiment, protein pharmaceutical reagents containing soluble protein of the present invention and/or membrane-bound protein anchored in a lipid-containing substrate incapable of stimulating a T cell response, are particularly useful for the treatment of autoimmune diseases, immunoproliferative diseases and in transplantation procedures. Protein pharmaceutical reagents containing membrane-bound protein anchored in a lipid-containing substrate capable of stimulating a T cell response, are particularly useful for the treatment of immunodeficiency diseases.

Another embodiment of the present invention relates to the use of recombinant molecules of the present invention as nucleotide formulations for therapeutic or experimental use, such therapeutic use is referred to as gene therapy. A recombinant molecule of the present invention can be used to produce a nucleotide pharmaceutical reagent. Diseases associated with immune function can be treated by genetic modification of autologous or allogenic populations of cells involved in an immune response. For example, diseases such as autoimmune diseases, immunodeficiency diseases, immunoproliferative diseases, graft-host rejection and other genetic diseases related to a deficiency, an oversensitivity or malfunction of a cell involved in an immune response, can be corrected by introduction of a recombinant molecule of the present invention.

-43-

The reocmbinant molecule used in gene therapy can be those that do not integrate into the genome of the a host cell or those that do integrate. Recombinant molecules that do integrate into the genome of a cell are particularly useful for introduction into pluripotent cells, such as stem cells or pluripotent hematopoietic cells. Recombinant molecules that do not integrate into the genome of a host cell are particularly useful for introduction into lineage-committed cells (e.g., immature or mature lymphocytes, erythrocytes and leukocytes). Recombinant molecules that do not integrate into the genome of a host cell can be non-replicating DNA sequences, or specific replicating sequences genetically engineered to lack the genome-integration ability.

Specific promoters can be employed in gene therapy applications based upon the type of cell being transformed. Thus, inducible production of a desired product encoded by transformed genes can be achieved. Suitable promoters for use in various vertebrate systems include those promoters disclosed in detail herein, In humans, a particularly useful promoter includes a cytomegolavirus IEP promoter.

Recombinant molecules can be delivered to an animal in a variety of methods including, but not limited to, (a)direct injection (e.g., as "naked" DNA or RNA molecules, such as is taught, for example in Wolff et al., 1990, *Science* 247, 1465-1468) or (b) packaged as a recombinant virus particle vaccine or as a recombinant

-44-

cell vaccine (i.e., delivered to a cell by a vehicle selected from the group consisting of a recombinant virus particle vaccine and a recombinant cell vaccine). A number of recombinant virus particles can be used as a recombinant virus particle vaccine or as a recombinant cell vaccine, including, but not limited to, those based on alphaviruses, poxviruses, adenoviruses, herpesviruses, and retroviruses. A recombinant molecule can also be associated with a lipid-based carrier prior to delivery to an animal. Preferred lipid-based carriers for delivering a recombinant molecule of the present invention include liposomes. A nucleotide pharmaceutical reagent of the present invention can further comprise aqueous carriers as described in detail herein.

Pharmaceutical reagents of the present invention can be administered to any animal, preferably to mammals, and even more preferably humans. Acceptable protocols to administer pharmaceutical formulations in an effective manner include individual dose size, number of doses, frequency of dose administration, and mode of administration. Modes of delivery can include any method compatible with prophylactic or treatment of a disease. Modes of delivery include, but are not limited to, parenteral, oral, intravenous, topical or local administration such as by aerosol or transdermally.

A pharmaceutical reagent of the present invention is useful for the treatment of any disease caused in part by abnormal stimulation or suppression of an immune response.

-45-

Such diseases include autoimmune diseases, immunodeficiency diseases, and immunoproliferative diseases. A pharmaceutical reagent of the present invention is also useful for treatments involving the transplanta-  
5 tion of organs and skin. Autoimmune diseases include, for example, systemic lupus, myasthenia gravis, rheumatoid arthritis, insulin dependent diabetes mellitus and experimental allergic encephalomyelitis. Immunodeficient diseases include, for example, human AIDS,  
10 hypogammaglobulinemia, DiGeorge Syndrome, chronic mucocutaneous candidiasis, GVH disease, combined immunodeficiency disease, Nezelof's Syndrome, episodic lymphopenia, and immunodeficiencies related to thymomas, eczema, thrombocytopenia, adenosine deaminase deficiency  
15 and dwarfism. Immunoproliferative diseases include, for example, lymphomas and leukemias. In addition, a pharmaceutical reagent of the present invention capable of stimulating a T cell response is useful for the treatment of specific disorders such as tumors, allergic responses  
20 and inflammation.

Experimental reagents of the present invention includes a protein formulation useful for, for example, screening for peptides capable of regulating T cell activity, antibodies that bind MHC protein complexed with  
25 peptide, for TCR's capable of binding MHC protein complexed with peptide, and for T cells bearing TCR capable of binding MHC protein complexed to peptide.

-46-

A method to screen for peptides capable of regulating T cell activity includes: (1) contacting a T cell with a reagent selected from the group consisting of, (i) a Peptide-L-MHC molecule comprising an antigenic peptide joined by a linker to an MHC segment, wherein said MHC segment is capable of forming a binding groove, (ii) a formulation in which the Peptide-L-MHC molecule of (i) is anchored to the plasma membrane of a cell essentially incapable of stimulating a T cell response, and (iii) a formulation in which said Peptide-L-MHC molecule of (i) is anchored to the plasma membrane of a cell capable of stimulating a T cell response, wherein the T cell to be contacted is capable of recognizing the MHC segment of the reagent; and (2) determining if the reagent stimulates IL-2 activity or alters signal transduction.

The following experimental results are provided for purposes of illustration and are not intended to limit the scope of the invention.

### Examples

#### 20 Example 1

This Example demonstrates that genes coding for peptides covalently associated to MHC Class II proteins by a linker can be expressed as stable soluble proteins capable of being recognized by T cells.

25 Murine class II genes encoding the extracellular domains of an IE  $\alpha$  chain protein (IE $\alpha^d$ ), an IE  $\beta$  chain protein (IE $\beta^k$ ), IA  $\alpha$  chain protein (IA $\alpha^d$ ), and an IA  $\beta$



-47-

chain (IAB<sup>d</sup>) protein, were prepared using polymerase chain reaction (PCR) amplification of cloned cDNA templates. To allow for secretion of fully assembled  $\alpha\beta$  dimers, these genes were truncated at the last codon prior to codons encoding the transmembrane and cytoplasmic portions of the proteins. Primers used for PCR amplification of the IE $\alpha^d$  gene were 5' TCCTCGAGAAATGGCCACAATTGGAG 3' and 3' CTTTGATTTCTCTTAATTCATGGTT 5'. Primers used for PCR amplification of the IE $\beta^k$  gene were 5' CCGGGAATTCAGCATGGTGTGGCTCC 3' and 3' AGACGTTCTTGTTGCATTCGTACGCC 5'. The alignment of the primers with their respective cDNA templates is shown in Table 1.

Genes encoding IA $\alpha^d$  and IAB<sup>d</sup> proteins were also produced by PCR amplification. Primers used for PCR amplification of the IA $\alpha^d$  gene were 5' TCCTCGAGAGGATGCCGTGCAGCAGAG 3' and 3' CTCGACTGGTCTTTGAATTCCATGGTT 5'. Primers used for PCR amplification of the IAB<sup>d</sup> gene were 5' TACGGAATTCTTAGAGATGGCTCTGCAGA 3' and 3' TCAGACGGGCCTCGTTCATTCGTACGCC 5'. The alignment of the primers with their respective cDNA templates is shown in Table 1. The restriction enzyme sites used for cloning the IE $\alpha^d$ , IE $\beta^k$ , IA $\alpha^d$  and IAB<sup>d</sup> genes into new multiple cloning sites (MCS) of a baculovirus transfer vector are also shown in Table 1.

Table 1.

E $\alpha^d$	5'-TCCTCGAGAAATGGCCACAATTGGAG-3' XhoI MetAlaThrIleGlyAlaLeu//LeuLeuProGluThrLysGluAsn*** KpnI 3'-CTTTGATTTCTCTTAATTCATGGTT-5'
5	5'-CCGGGAATTCAGCATGGTGGCTCC-3' EcoRI MetValTrpLeuProArg//GlnSerThrSerAlaGlnAsnLys*** SphI 3'-AGACGTTCTTGTTCATTCGTACGCC-5'
A $\alpha^d$	5'-TCCTCGAGAGGATGCCGTGCAGCAGAG-3' XhoI MetProCysSerArgAlaLeu//ProMetSerGluLeuThrGluThr*** KpnI 3'-CTCGACTGGTCTTTGAATTCATGGTT-5'
10	5'-TACCGAATTCCTAGAGATGGCTCTGCAGA-3' EcoRI MetAlaLeuGlnIleProSer//GlnSerGluSerAlaArgSerLys***SphI 3'-TCAGACGGGCCTCGTTCATTCGTACGCC-5'

-49-

Using PCR amplification, a hybrid IEB<sup>k</sup> nucleic acid molecule was produced containing sequences encoding amino acid residues 91-103 of moth cytochrome c (MCC Peptide (91-103), a linker containing a thrombin cleavage site, and the IEB<sup>k</sup> gene. The hybrid molecule was prepared as follows. Referring to Table 2, a first fragment (fragment 234-328) was produced encoding the leader and the first three codons of the  $\beta$ 1 domain of IEB<sup>k</sup>, and the first 11 codons of the MCC peptide using Primer #234 (5' TACGGAATTCAGCATGGTGTGGCTCCC 3') and Primer #328 (5'ACCGGACGAAGTTTATCCGTTAGTCCAGTCGGGCCCTCAGAGACTGGTT 3') on an IEB<sup>k</sup> cDNA template. Primer #234 contains an EcoRI

### E8k with moth cytochrome peptide

[illegible]

-51-

restriction enzyme site and Primer #328 contains an XmaI restriction enzyme site. Fragment 234-328 was used as a template for a second PCR fragment (fragment 234-329) in which fragment 234-328 was extended by adding sequences encoding the remainder of the MCC peptide and the first 10 codons of the linker were added using Primer #329 (5' GGGGCACCGT<sup>u</sup>GATCACTCGGTGGTGGAGGGAACCACCGGACGAAGTTTAT 3'). Primer #329 contains an SpeI site. Fragment 234-329 was used as a template for a third PCR fragment (fragment 234-330) in which fragment 234-329 was extended by adding sequences encoding the remainder of the linker and residues 4-8 of the  $\beta 1$  domain using Primer #330 (5' TTTTGGTACCAGACCTGGGTGGAGGAGGTCTCGGGGCACCGTGA<sup>u</sup>CTCACTCG 3'). Primer #330 contains a SpeI site and an NcoI site. Fragment 234-330 was then digested with EcoRI and NcoI and cloned into EcoRI and NcoI digested pBACp10H vector that had the IE $\alpha^d$  cloned after the P10 promoter and IE $\beta^k$  cloned after the polyhedrin promoter (described in detail below). The nucleic acid molecule having sequences encoding a moth cytochrome C (91-103) peptide, a linker and an IE $\beta^k$  gene encoding the IE $\beta^k$   $\beta 1$  and  $\beta 2$  domains is referred to as N-IE $\beta^k$ -MCC.

Using PCR amplification, a hybrid IAB $^d$  nucleic acid molecule was produced containing sequences encoding amino acid residues 327-339 of chicken ovalbumin (COVA Peptide (327-339), a linker containing a thrombin cleavage site, and the IAB $^d$  gene. The hybrid molecule was prepared as

-52-

follows. Referring to Table 3, a first fragment (fragment 261-331) was produced encoding the leader and the first 3 codons of the  $\beta 1$  domain of IAB<sup>d</sup> and the first 7 codons of the cOVA peptide using Primer #261 (5'

- 5 TACGGAATTCTTAGAGATGGCTCTGCAGAT 3') and Primer #331 (5' AGAGTCGTACCCGTCGTACATGCCTCAAAGGCGGGAGTCAGGGCCCCGACGAGT 3') on an IAB<sup>d</sup> cDNA template. Primer #261 contains an EcoRI

Abd' with Chicken Ova1bumin peptide

[illegible]

-54-

site and Primer #331 contains an XmaI site. Fragment 261-331 was used as a template for a second PCR fragment (fragment 261-332) in which the fragment 261-331 was extended by adding sequences encoding the remainder of the cOVA peptide and the first 8 codons of the linker were added using Primer #332 (5' CCGTGATCACTCGGGGGTGGAGGAGACGGTCGGAGTAACTAGAGTCGTACCCGTC 3'). Primer #332 contains an SpeI site.

Using PCR amplification, a third fragment (fragment 333-259) was produced which containing sequences encoding the IAB<sup>d</sup>  $\beta$ 1 domain (minus the first three codons) and a portion of the IAB<sup>d</sup>  $\beta$ 2 domain. Fragment 333-259 was produced using Primer #333 (5' GGCTCACTAGTGCCCCGAGGCTCTGGAGGTGGAGGCTCCGAAAGGCATTTTC 3') and Primer #259 (5' GCGTACGAACGAATGAACGAGGCCCGTCTGAG 3') on an IAB<sup>d</sup> cDNA template. Primer #333 contains an SpeI site and Primer #259 contains an SphI site.

Fragment 261-332 and fragment 333-259 were mixed in solution and used as PCR templates for Primer #261 and Primer #259 to form fragment 261-259 encoding the IAB<sup>d</sup> leader, the cOVA peptide, the linker and the IAB<sup>d</sup> protein. Fragment 261-259 was digested with EcoRI and SphI and cloned after the polyhedrin promoter of a pBACp10H vector which had the IAB<sup>d</sup> gene already cloned after the P10 promoter (described in detail below). The nucleic acid molecule having sequences encoding the cOVA (327-339)



-55-

peptide, a linker and an  $IA\beta^d$  protein including the  $\beta 1$  and  $\beta 2$  domains is referred to as N- $IA^d$ -OVA

Table 4 lists the nucleic acid and protein sequences of the  $IE\beta^k$ -MCC and  $IA\beta^d$ -OVA from the promoters (described below), through the leaders, peptides and linkers, and into the  $\beta 1$  domains. Similar sequences are shown for  $IE\beta^k$  or  $IA\beta^d$  without nucleic acid sequences encoding antigenic peptide or linker.

Table 4.

IE $\beta$ <sup>k</sup>

TTTACTGTTTCGTAACAGTTTGTAAATAAAAAACCTATAAATACCGAATTCAGCATCGTGCGCTCCCCAGAGTTCCTCTGT  
 ----- polyhedrin promoter ----->Eco RI MetValTrpLeuProArgValProCys  
 GTCCACCTGTGATCCTGTTGCTGACAGTGCTGACCCCTCCAGTCCCTTTGGTCAGAGACTCCAGACCATCGTTTTTGAATAC  
 ValAlaAlaValIleLeuLeuLeuThrValLeuSerProProValAlaLeuValArgAspSerArgProTrpPheLeuGluTyr  
 ----- Leader ----->E<sub>8</sub><sup>k</sup>(81) -----

Moth Cyto C Peptide Covalently Linked to IE $\beta$ <sup>k</sup>

TTTACTGTTTCGTAACAGTTTGTAAATAAAAAACCTATAAATACCGAATTCAGCATCGTGCGCTCCCCAGAGTTCCTCTGT  
 ----- polyhedrin promoter ----->Eco RI MetValTrpLeuProArgValProCys  
 GTCCACCTGTGATCCTGTTGCTGACAGTGCTGACCCCTCCAGTCCCTTTGGTCAGAGACTCCCCGCTGACCTGATTCCCTAT  
 ValAlaAlaValIleLeuLeuLeuThrValLeuSerProProValAlaLeuValArgAspSerArgAlaAspLeuIleAlaTyr  
 ----- Leader ----->E<sub>8</sub><sup>k</sup>(81)>----- Moth Cyto C  
 TTGAACGACCCACCAAGCGAGCTGCTGCTCACTAGTCCACCGCGCTCTGGAGGAGGTCCGTCCAGACCATCGTTTTTGCAG  
 LeuLysGlnAlaThrLysGlyGlyGlyGlySerLeuValProArgGlySerGlyGlyGlySerArgProTrpPheLeuGlu  
 Peptide (91-103)>----- Linker ----->----- Thrombin ----->----- Linker ----->----- E<sub>8</sub><sup>k</sup>(81) -----

IA $\beta$ <sup>d</sup>

TTTACTGTTTCGTAACAGTTTGTAAATAAAAAACCTATAAATACCGAATTCCTAGAGATCGCTCTCCAGATCCCCAGCCTC  
 ----- polyhedrin promoter ----->Eco RI MetAlaLeuGlnIleProSerLeu  
 CTCCTCTCAGCTCCTGTGCTGCTGATCGTCTGACGACCCCGGACTGACCGCCGAACTCCGAAAGCCATTTCGTGCTG  
 LeuLeuSerAlaAlaValValValLeuMetValLeuSerSerProGlyThrGluGlyGlyAsnSerGluArgIlePheValVal  
 ----- Leader ----->A<sub>8</sub><sup>d</sup>(81) -----

COVA Peptide Covalently Linked to IA $\beta$ <sup>d</sup>

TTTACTGTTTCGTAACAGTTTGTAAATAAAAAACCTATAAATACCGAATTCCTAGAGATCGCTCTCCAGATCCCCAGCCTC  
 ----- polyhedrin promoter ----->Eco RI MetAlaLeuGlnIleProSerLeu  
 CTCCTCTCAGCTCCTGTGCTGCTGATCGTCTGACGACCCCGGACTGACCGCCGAACTCCGTACATGCTCCCATGCT  
 LeuLeuSerAlaAlaValValValLeuMetValLeuSerSerProGlyThrGluGlyGlyAsnSerValIleAlaAlaIleAla  
 ----- Leader ----->A<sub>8</sub><sup>d</sup>(81)>----- COVA  
 CAGATCAATGACCTCCAGAGGAGCTGACGCTCACTAGTCCCGGAGCTCTGGAGTCCAGGCTCCGAAAGCCATTTCGTG  
 GluIleAsnGluAlaGlyArgGlyGlyGlyGlySerLeuValProArgGlySerGlyGlyGlyGlySerGluArgIlePheVal  
 Peptide (327-339)-->----- Linker ----->----- Thrombin ----->----- Linker ----->----- A<sub>8</sub><sup>d</sup>(81) -----

-57-

The nucleic acid sequences encoding the  $\alpha$  and  $\beta$  chains of IE and IA ( $IE\alpha^d$ ,  $IE\beta^k$ ,  $IE\beta^k$ -MCC,  $IA\alpha^d$ ,  $IAB^d$ , and  $IA\beta^d$ -OVA sequences) were cloned into the P10 and polyhedrin MCS's of the dual promoter baculovirus transfer vector, pBACp10H (Pharmlngen). The vector was altered using oligonucleotides and PCR amplification to replace both the EcoRI and BglII sites after the P10 promoter and the BamHI site after the polyhedrin promoter with new MCS's. The DNA sequences through the new MCS's were:

10

P10- CACTGATCCTCGAGGGGGTGACCGGTCCGGAGGGGTACCAATTCCAG

Polyhedrin-AAATACGGAATTCGGGTCGACGGAGATCTGGGCATGCGGGGATCCGG

To form the recombinant molecule pIE<sup>kd</sup>-MCC encoding an  
15 IE<sup>kd</sup>  $\alpha\beta$  dimer containing the MCC peptide and the linker, the  
gene encoding the IE $\alpha^d$  protein was ligated into the XhoI and  
KpnI sites following the P10 promoter, and the IE $\beta^k$ -MCC  
nucleic acid molecule was ligated into the EcoRI and NcoI  
sites after the polyhedrin promoter. The same procedure  
20 was performed to ligate the gene encoding the IE $\beta^k$  protein  
into pBACp10PH to form the recombinant molecule pIE<sup>kd</sup>  
encoding an IE<sup>kd</sup>  $\alpha\beta$  dimer.

To form the recombinant molecule pIA<sup>d</sup>-OVA encoding an IA<sup>d</sup> αβ dimer containing the cOVA peptide and the linker, the gene encoding the IAα<sup>d</sup> protein was ligated into the EcoRI and SphI sites after the polyhedrin promoter and the IAβ<sup>d</sup>-OVA nucleic acid molecule was ligated into the EcoRI and

-58-

SphI sites after the polyhedrin promoter. The same procedure was used to ligate the gene encoding the IAB<sup>d</sup> protein into pBACp10PH to form the recombinant molecule P-IA<sup>d</sup> encoding an IA<sup>d</sup>  $\alpha\beta$  dimer.

5 pIE<sup>kd</sup>-MCC, pIE<sup>kd</sup>, pIA<sup>d</sup>-OVA and pIA<sup>d</sup> were separately recombined into the Baculogold baculovirus (Pharmlingen) in SF9 cells by co-transfection to produce recombinant stocks of virus. The initial recombinant virus stocks were cloned by infection of SF9 cells at limiting dilution in 96-well  
10 plates. A large viral stock of a clone was produced for subsequent large scale protein production of secreted IE<sup>kd</sup>-MCC, IE<sup>kd</sup>, IA<sup>d</sup>-OVA and IA<sup>d</sup> protein.

Recombinant viral stocks containing pIE<sup>kd</sup>-MCC, pIE<sup>kd</sup>, pIA<sup>d</sup>-OVA and pIA<sup>d</sup> recombinant molecules were expressed in  
15 baculovirus infected insect cells to produce secreted protein. High 5 insect cells (Invitrogen) at 5-10 x 10<sup>5</sup>/ml in TMN-FH media were infected at a multiplicity of infection of 5-10 with baculovirus carrying pIE<sup>kd</sup>, pIA<sup>d</sup>, pIE<sup>kd</sup>-MCC, or pIA<sup>d</sup>-OVA recombinant molecules. Five to six  
20 days later culture supernatants were harvested by centrifugation.

The secreted proteins were immunoaffinity purified using immobilized anti- $\beta$ -chain monoclonal antibodies (14-4-4 specific for IE<sup>k</sup>, and M5/114 specific for IAB<sup>d</sup>). The  
25 protein was eluted with a basic buffer at pH 10.5 and immediately neutralized. SDS-PAGE analysis was performed to measure relative amounts of protein recovery. The

-59-

results showed in all cases equimolar  $\alpha$  and  $\beta$ -chain in the eluted protein indicating initial secretion of  $\alpha\beta$  heterodimers. The overall yield was 0.5 to 1.5mg/liter of culture media.

5        The stability of the immunoaffinity purified  $\alpha\beta$  dimers were analyzed by HPLC gel filtration. For gel filtration analysis, ~50ug of each protein in 20ul was loaded on a Shodex Protein KW-804 HPLC gel filtration column of dimensions 8mm x 300mm (total volume ~15ml). The column  
10        was eluted at 0.5ml/min. in PBS and the OD<sub>280</sub> of the eluate followed. The four elution profiles shown were normalized to the same total OD<sub>280</sub>. Referring to Fig. 2, the elution positions of molecular weight standards are shown at the top of the Figure: bovine serum albumin, 67kD; ovalbumin,  
15        43kD; and chymotrypsinogen, 25kD. In Fig. 2a, IE<sup>dk</sup> is represented as O--O; IE<sup>k/d</sup>-MCC is represented as ●--●. In Fig. 2b, IA<sup>d</sup> is represented as O--O; and IA<sup>d</sup>-OVA is represented as ●--●.

20        The results shown in Fig. 2b indicate that both IE<sup>k/d</sup> and IA<sup>d</sup> protein showed high molecular weight aggregates and apparent size heterogeneity even in the  $\alpha\beta$  dimer peak. IA<sup>d</sup> appeared particularly unstable with considerable dissociation by free  $\alpha$  and  $\beta$  chains after elution from the immunoaffinity column. The lack of stability of the IE<sup>k/d</sup>  
25        and IA<sup>d</sup> proteins is believed to be, in large part due to the lack of antigenic peptide bound to the binding groove of the two proteins.

-60-

In contrast, IE<sup>k/d</sup>-MCC protein was greatly stabilized by the covalently attached MCC peptide, migrating sharply as a uniform  $\alpha\beta$  heterodimer (see Fig. 2a). Likewise, although IA<sup>d</sup>-OVA still formed some high molecular weight aggregates, it also was considerably stabilized by the covalently attached OVA peptide with most of the protein migrating as a uniform  $\alpha\beta$  heterodimer. This stabilization suggests that the peptides were engaged by the peptide binding grooves of IE<sup>k/d</sup>-MCC and IA<sup>d</sup>-OVA protein. Results from this experiment indicate that both IE<sup>k/d</sup>-MCC and IA<sup>d</sup>-OVA protein have peptide bound to their binding grooves and that both proteins are stable than IE<sup>k/d</sup> and IA<sup>d</sup> proteins which do not have peptide bound their binding grooves.

The stability of MHC protein interaction with peptide was also measured by incubating IE<sup>k/d</sup>-MCC and IA<sup>d</sup>-OVA protein in 1% SDS at room temperature or 94°C. When the IE<sup>k/d</sup>-MCC protein was tested in this manner, its chains remained associated at room temperature, but not at 94°C. In contrast, the IA<sup>d</sup>-OVA  $\alpha$  and  $\beta$  chains dissociated at both temperatures. These results suggest that peptide alone is sufficient to stabilize the IE<sup>k/d</sup>-MCC protein in 1% SDS. However, peptide is not sufficient to stabilize the IA<sup>d</sup>-OVA protein, perhaps due to the absence of the  $\alpha$  and  $\beta$ -chain transmembrane regions.

The IE<sup>k/d</sup>-MCC and IA<sup>d</sup>-OVA protein were then tested for their ability to present peptide, by measuring IL-2 production by T cell hybridomas following incubation with

-61-

immobilized IE<sup>k/d</sup>-MCC and IA<sup>d</sup>-OVA protein. Immunoaffinity purified IE<sup>dk</sup>, IA<sup>d</sup>, IEdk-MCC, and IA<sup>d</sup>-OVA were prepared as described above. In addition, an attempt was made to produce IE<sup>dk</sup> and IA<sup>d</sup> MHC-peptide complexes by mixing: (1) synthetically produced MCC (88-103) peptide mixed with IE<sup>dk</sup> protein (IE<sup>dk</sup> + MCC); and (2) synthetically produced OVA (327-339) was mixed with IA<sup>d</sup> protein (IA<sup>d</sup> + OVA). The mixtures were incubated overnight in 50μl of citrate buffer at pH 5.0, at 37°C and at a concentration of 10μg of the Class II molecules and 10μg of the peptide. Following incubation, the mixtures were neutralized and unbound peptide was removed using a Centricon 10 filter unit.

Aliquots of the IE<sup>k/d</sup>-MCC and IA<sup>d</sup>-OVA protein were digested by a 2 hour incubation of 10μg of the complex with 2 x 10<sup>-3</sup> units of thrombin at pH 6.6. Such conditions digested at least 80% of the complex as assessed by SDS-PAGE. Different amounts of the various Class II preparations were immobilized by overnight non-specific adsorption to the bottom of wells of 96 well Immulon II plates. Either 5KC-73.8 (IE<sup>dk</sup> + MCC specific) (5KC) or DO-11.10 (IA<sup>d</sup> + OVA specific) T cell hybridomas (10<sup>5</sup> cells) were added in 250ul of tissue culture medium to each coated well of the 96-well plate. The plates were cultured overnight and the amount of IL-2 produced by the hybridomas was assessed. The results are shown in Fig. 3. Fig. 3a shows the results of IL-2 production by 5KC-73.8 cells in the presence of IE<sup>dk</sup>-MCC (●), IE<sup>dk</sup> + MCC (■), thrombin

-62-

treated IE<sup>dk</sup>-MCC (★), and IE<sup>dk</sup> (▼) and IA<sup>d</sup>-OVA (♦) samples as controls. The results indicate that the hybridoma responded better to the covalent IE<sup>dk</sup>-MCC complex than to purified IE<sup>dk</sup> subsequently loaded with the MCC peptide (IE<sup>dk</sup> + MCC). In addition, cleavage of the linker by thrombin did not affect the ability of the IE<sup>dk</sup>-MCC complex to induce IL-2 production.

Fig. 3b shows the results of IL-2 production by DO-11.10 cells in the presence of IA<sup>d</sup>-OVA (■), IA<sup>d</sup> + OVA (×), thrombin treated IA<sup>d</sup>-OVA (+), and IE<sup>dk</sup>-MCC (●) and IA<sup>d</sup> (▲) samples as controls. The results indicate that both IA<sup>d</sup>-OVA and thrombin treated IA<sup>d</sup>-OVA induced IL-2 production by the T cell hybridoma. Conversely, IA<sup>d</sup> + OVA, IE<sup>dk</sup>-MCC and IA<sup>d</sup> protein failed to induce an IL-2 response.

Two other T cell hybridomas specific for IA<sup>d</sup> plus OVA peptide were tested in similar assays. One responded in the same way as that illustrated above. Another hybridoma failed to respond to IA<sup>d</sup>-OVA regardless of whether or not the linker had been cleaved with thrombin. It is possible that recognition of the peptide by the receptor on this T cell hybridoma is context sensitive, i.e. it is inhibited in some way by the presence of the few amino acids of the β1 domain of IA<sup>d</sup> on the N-terminus of the peptide.

The results shown in Fig. 3 indicate that the a covalent association of peptide and Class II protein by a linker forms a Peptide-MHC complex that can be recognized by T cells specific for the combination. Moreover, the



-63-

covalently associated Peptide-MHC complex induces a better immune response than complexes formed by mixing the peptide with the MHC protein in solution. The results also indicate that the covalently associated Peptide-MHC complex is more stable than an MHC protein in the absence of peptide. In both cases treatment of the peptide/MHC covalent complex with thrombin to cleave the linker between them only modestly improved T cell hybridoma recognition. This indicates that the linker most likely extends from the C-terminal end of the peptides around the side rather than over the top of the Class II  $\alpha$  chain  $\alpha$  helix in order to reach the N terminal end of the Class II  $\beta$  chain (see Fig. 1).

Together all these data show that genes coding for peptides covalently associated to MHC Class II proteins by a linker can be expressed as soluble proteins capable of being recognized by T cells. The data also indicate that the peptides linked to the MHC protein form stable complexes more effective at stimulating a T cell response than complexes formed by mixing the peptide with the MHC protein.

#### Example 2

This Example demonstrates that genes coding for peptides covalently associated to MHC Class II proteins by a linker can be expressed as stable membrane-bound proteins capable of being recognized by T cells.

-64-

Using PCR amplification, a hybrid  $IA\beta^b$  nucleic acid molecule was produced containing sequences encoding amino acid residues 56-73 of  $IE\alpha^d$  ( $IE\alpha^d$  Peptide (56-73), a linker containing a thrombin cleavage site, and an  $IA\beta^b$  gene, including the extracellular, transmembrane and cytoplasmic domains. The hybrid molecule was prepared as follows. Referring to Table 5, a first fragment (fragment 362-363) was produced encoding the leader and the first 4 codons of the  $\beta 1$  domain of  $IA\beta^b$ , and the first 12 codons of the  $IE\alpha^d$  peptide using Primer #362

(5' CCCGAGCTCGGGAATTCTTAGAGATGGCTCTGCAG 3') and #363  
(5' TTACAACCGGTCACGTGGGACTCGGAGTTTCGATCGAAGCCTCAGAGGCGGG 3') on an  $IA\beta^b$  cDNA template. Primer #362 contains an EcoRI

## ASb with Ead Peptide in pTZ18R

[illegible]

-66-

site and Primer #363 contains an NheI site. Fragment 362-363 was used as a template for a second PCR fragment (fragment 362-364) in which fragment 362-363 was extended by adding sequences encoding the remainder of the IE $\alpha^d$  peptide and the first 7 codons of the linker were added using Primer #364

(5' GGTGGCCTAGGTGGTGGAGGTCGGAACAGCTGTCGTTACAACCGGTCACG 3').

Primer #364 contains a SalI and a BamHI site.

Using PCR amplification, a third fragment (fragment 365-366) was produced which containing sequences encoding the IAB $\beta$   $\beta$ 1 (minus the first four codons),  $\beta$ 2, transmembrane and cytoplasmic domains. Fragment 365-366 was produced using Primer #365

(5' GGTGGATCCGGTGGAGGGGGAAGTGGAGGTGGAGGGTCTGAAAGGCATTTTCGTG 3') and Primer #366 (5' CGGTTCGAAGGCTTAAGAGTGACGTCCTCGGGACG 3'). Primer #365 contains a BamHI site and Primer #366 contains both an EcoRI and a HindIII site. A nucleic acid molecule was formed from the above fragments having sequences encoding an IE $\alpha^d$  (56-73) peptide, a linker and an IAB $\beta$  protein, referred to as N-IA $\beta$ -Ea.

For transfection into B cells, the recombinant molecule pM12-IA $\beta$ -Ea was produced by digesting fragment 362-364 with EcoRI and BamHI and ligating the digested fragment into EcoRI/BamHI digested carrier vector pTZ18R to form a pTZ-IA $\beta$ -Ea(362-364) construct. Fragment 365-366 was then digested with BamHI and HindIII and the digested fragment was ligated into the pTZ-IA $\beta$ -Ea(362-364) construct that had

-67-

been digested with BamHI and HindIII to form a pTZ-IA<sup>b</sup>-Ea construct. The pTZ-IA<sup>b</sup>-Ea construct was then digested with EcoRI and subcloned into the expression vector pDOI-5 (obtained from D. Mathis and C. Benoit, containing a class II promoter and enhancer region, a  $\beta$ -globin intron and EcoRI cloning site) to form the recombinant molecule pM12-IA<sup>b</sup>-Ea encoding IA<sup>b</sup>-Ea protein. pM12-IA<sup>b</sup>-Ea recombinant molecules having sequences encoding IA<sup>b</sup>-Ea protein in the correct orientation were identified by nucleic acid sequencing multiple pM12-IA<sup>b</sup>-Ea recombinant molecules.

The recombinant molecule pFIB-IA<sup>b</sup>-Ea was produced for transfection into fibroblast cells by subcloning the pTZ-IA<sup>b</sup>-Ea construct described above with EcoRI and subcloning the EcoRI fragment into EcoRI digested expression vector pH $\beta$ AcPr-1-neo (obtained from S. Hedrick, containing the human  $\beta$ -actin promoter and enhancer, and a sequence encoding neomycin resistance). The orientation of each cloned insert was determined after cloning by nucleic acid sequencing.

Table 6 lists the nucleic acid and protein sequence of the IA  $\beta$  chain from the leader, through the peptide and linker, into the  $\beta$ 1 domain. A similar construction was made for IA $\beta^b$  without nucleic acid sequences encoding antigenic peptide as controls.

### Construction of IAB<sup>b</sup> with E $\alpha^d$ Peptide

IAB<sup>b</sup> Alone

IAB<sup>b</sup> with Eα<sup>d</sup> Peptide

CCTGTCGACAAGGCTGGAGGTGGTGGATCCGGTGGAGGGGGAAGTGGAGGTGGAGGCTCGAAAGGCATTTCT  
 A V D K A G G G G S G G G G S G G G S E R H F  
 -----><----- Linker -----><--β1---

-69-

A B cell line M12.C3 was transfected with the recombinant molecule pM12-IA<sup>b</sup>-Ea or a recombinant molecule encoding an IA<sup>b</sup> protein. Using standard fluorescence activated cell sorter analysis (FACS analysis), two different antibodies were used to detect expression of IA<sup>b</sup>-Ea protein on the surface of the M12 cells, an anti-IA<sup>b</sup> antibody and an antibody (5A) specific for IA<sup>b</sup> protein bound by IE $\alpha^d$  peptide. The results shown in Fig. 4 indicate that the M12.C3 cells transfected with IA<sup>b</sup>-Ea protein react well with both antibodies. Untransfected M12.C3 cells and normal spleen cells are shown as negative controls. Thus, the IA<sup>b</sup>-Ea protein is expressed in M12.C3 cells and reaches the cell surface. Moreover, the covalently bound peptide is bound to the peptide-binding groove of the IA<sup>b</sup> protein as indicated by the binding of the 5A antibody.

An experiment was performed to determine the extent of binding of the covalently associated IE $\alpha^d$  to the binding site of the associated IA<sup>b</sup> protein. M12.C3 cells bearing either IA<sup>b</sup>-Ea protein or IA<sup>b</sup> protein were mixed with T hybridoma cells specific for IA<sup>b</sup> protein bound by COVA peptide (BO.97.10). Increasing concentrations of either COVA peptide (described in Example 1) or ovalbumin was added to the mixture and the amount of IL-2 produced by the hybridoma was measured. The COVA peptide is known to be capable of binding to the binding site of IA<sup>b</sup> protein. Thus, the COVA peptide will bind to any IA<sup>b</sup> protein not bound by peptide. The IL-2 production is a measurement of

-70-

the amount of  $IA^b$  protein bound by cOVA peptide present in the mixture. The results are shown in Fig. 5.

M12.C3 cells bearing  $IA^b$ -Ea protein (■) did not stimulate IL-2 production by BO.97.10 cells in the presence of ovalbumin. M12.C3 cells bearing  $IA^b$  protein (□) did stimulate IL-2 production in the presence of a substantial concentration of ovalbumin. These results indicate that ovalbumin is being taken up by the M12.C3 cells, processed and presented on the cell surface in association with the  $IA^b$ -Ea protein but not in association with  $IA^b$ -Ea protein. Thus, the  $IA^b$ -Ea protein is not available to bind ovalbumin peptide inside the cell, most likely because the binding site of the protein is bound by the covalently associated  $IE\alpha^d$  peptide.

As expected, M12.C3 cells bearing  $IA^b$  protein (□) did stimulate IL-2 production in the presence of cOVA peptide. M12.C3 cells bearing  $IA^b$ -Ea protein (■) also stimulated IL-2 production in the presence of cOVA. However, the  $IA^b$ -Ea protein bearing cells required about 10-fold more cOVA and stimulated about 10-fold less IL-2 production than the  $IA^b$  protein bearing cells. Thus, only about 10% of the  $IA^b$ -Ea protein was bound by cOVA peptide and about 90% of the  $IA^b$ -Ea protein had  $IE\alpha^d$  bound to the binding site of the  $IA^b$  protein. The results also indicate that the covalently associated  $IE\alpha^d$  peptide of the  $IA^b$ -Ea protein is bound in the  $IA^b$  binding site in a stable manner.



-71-

The ability of IA<sup>b</sup>-Ea protein bearing M12.C3 cells to present peptide was tested by measuring IL-2 production by a T cell hybridoma specific for IA<sup>b</sup>-Ea protein. M12.C3 cells bearing IA<sup>b</sup>-Ea protein or IA<sup>b</sup> protein (10<sup>5</sup> cells/well) were mixed with BE-20.6 T hybridoma cells (10<sup>5</sup> cells/well) and cultured for 24 hours. Following incubation, the amount of IL-2 produced by the hybridomas was measured. The results indicate that IA<sup>b</sup>-Ea protein M12.C3 cells were capable of inducing IL-2 production by the hybridoma while IA<sup>b</sup> protein bearing M12.C3 cells were not capable of inducing IL-2 production (see Fig. 6). Thus, the covalently bound peptide is bound to the peptide-binding groove of the IA<sup>b</sup> protein and expressed on the surface of the B cell in a manner such that the complex can induce a T cell response.

In a second experiment, fibroblasts were transfected with the recombinant molecule pFIB-IA<sup>b</sup>-Ea or a recombinant molecule encoding an IA<sup>b</sup> protein were transfected into fibroblast cells. Expression of IA<sup>b</sup>-Ea protein on the surface of the fibroblasts was analyzed by FACS analysis using the same antibodies described above. As shown in Fig. 7, the fibroblasts transfected with the recombinant molecule encoding IA<sup>b</sup>-Ea protein react well with both anti-IA<sup>b</sup> antibody and antibody specific for IA<sup>b</sup> protein bound by IEα<sup>d</sup> peptide (5A). Thus, the proteins encoded by the transfected IA<sup>b</sup>-Ea recombinant molecule were well expressed

-72-

in fibroblast cells and the  $IA^b$ -Ea protein reaches the cell surface of the fibroblast.

Similar to the experiments performed with the B cells, fibroblast cells bearing  $IA^b$ -Ea protein or  $IA^b$  protein were tested to determine the extent of binding of the covalently associated  $IE\alpha^d$  to the binding site of the  $IA^b$  protein. Fibroblasts bearing either  $IA^b$ -Ea protein or  $IA^b$  protein were mixed with BO.97.10 T hybridoma cells. Increasing concentrations of cOVA peptide was added to the mixture and the amount of IL-2 produced by the hybridoma was measured. The results are shown in Fig. 8. As expected, the fibroblasts bearing  $IA^b$  protein ( $\square$ ) did stimulate IL-2 production in the presence of cOVA peptide. Fibroblasts bearing  $IA^b$ -Ea protein ( $\blacksquare$ ) stimulated about 10-fold less IL-2 production and required about 10-fold more cOVA peptide. Thus, similar to the  $IA^b$ -Ea protein produced in B cells, about 90% of the  $IA^b$ -Ea protein produced in fibroblasts are bound by  $IE\alpha^d$  peptide.

Fibroblast cells bearing  $IA^b$ -Ea protein or  $IA^b$  protein were tested for their ability to induce IL-2 production by three different T cell hybridomas, BE-20.15, BE-16 or BE-36. The hybridoma cells and the fibroblast cells were incubated according to the method described above and the amount of IL-2 production was measured. The results shown in Fig. 9 indicate that fibroblast cells bearing  $IA^b$ -Ea protein were capable of inducing IL-2 production while fibroblasts bearing  $IA^b$  protein did not induce IL-2

-73-

production. These results demonstrate that MHC protein that has a peptide covalently associated via a linker, can be expressed in a cell type that does not typically express MHC protein, and that the Peptide-MHC complex can be  
5 recognized by a hybridoma, resulting in stimulation of IL-2 production.

Together all these data show that genes coding for peptides linked to MHC Class II proteins can be expressed as membrane-bound protein in cells. The covalently bound  
10 peptide can bind to the groove of the MHC protein and be recognized by antibodies or T cells.

### Example 3

This example demonstrates that a gene encoding peptides covalently associated to an MHC Class II protein by a linker can be expressed as a transgene in mice.

#### A. Production of IEB<sup>k</sup>-MCC Transgenic Mice

A nucleic acid molecule was produced using residues 91-103 of moth cytochrome c (MCC Peptide (91-103)), linker, and IEB<sup>k</sup> encoding genes described in detail in Example 1 and was subcloned behind a hemoglobin  $\beta$ -chain promoter. The resulting recombinant molecule is referred to herein as pIEB<sup>k</sup>-MCC-Tg. Numerous copies of pIEB<sup>k</sup>-MCC-Tg were injected into the nuclei of fertilized eggs removed from (B1/6xSJL)F2 mice and the eggs replaced into mothers. Two mice were identified that expressed the IEB<sup>k</sup>-MCC transgene. These mice are referred to as founders. Transgenic progeny

-74-

produced from such founders were indistinguishable from the founders. Transgenic progeny were then crossed with H-2<sup>k</sup>.

B. Location of Expression of IE<sup>k</sup>-MCC in Transgenic Mice

In a first experiment, cells were isolated from the bone marrow, spleen and lymph nodes of transgene positive H-2<sup>k</sup> mice. The isolated cells were then assayed (using methods described in Example 1) for their ability to stimulate T cell hybridomas specific for IE<sup>k</sup> with bound MCC 91-103 peptide. The cells were tested either with or without added antigen (MCC 88-103).

Referring to Fig. 10, in the absence of antigen, the T cell hybridoma responded to cells isolated from the bone marrow and the spleen but not to those isolated from the lymph nodes. The results indicate that the transgene is being expressed in red blood cell precursors because, at the age the donor mice were used (5 weeks), there are abundant amounts of red blood cell precursors in the bone marrow and spleen, but none in the lymph nodes. Results using the control samples with antigen added indicate that the isolated lymph node cell population did contain IE<sup>k</sup>-bearing cells which could present antigen, but not the transgenic IE<sup>k</sup>-MCC.

To confirm that the transgenic IE<sup>k</sup>-MCC protein is expressed on red blood cell precursors or red blood cells, bone marrow or spleen transgene positive cells isolated from H-2<sup>k</sup> mice were sorted for the presence or absence of Ter 119 antigen. Ter 119 antigen is a protein that is

-75-

found on the surface of later red blood cell precursors and red blood cells but not on other hematopoietic cells.

Using standard fluorescence activated cell sorter techniques (FACS), populations of bone marrow or spleen cells were incubated with fluorescein-labelled anti-Ter 119 antibodies using standard conditions known in the art. The labelled cells were then sorted by FACS to obtain cells having bound anti-Ter 119 antibody. The FACS sorted Ter 119 positive transgene positive cells were then assayed for their ability to stimulate T cell hybridomas specific for IE<sup>k</sup> with bound MCC 91-103 peptide using the method described in Example 1.

The results indicate that the Ter 119 positive cells stimulated T cells specific for IE<sup>k</sup> with bound MCC 91-103 peptide in the absence of added MCC 88-103 peptide (see Fig. 11). Thus, the transgenic IE<sup>k</sup>-MCC protein is expressed on later red blood cell precursors and red blood cells contained in the populations of bone marrow and spleen cells isolated from the transgenic H-2<sup>k</sup> mice.

#### Example 4

This example demonstrates that IE<sup>k</sup> protein covalently attached to MCC 91-103 reduces the number of T cells specific for IE<sup>k</sup> with bound MCC 91-103 peptide in mice.

Transgenic progeny expressing transgenic IE<sup>k</sup>-MCC protein were crossed with a strain of mice expressing H-2<sup>k</sup> and a transgenic T cell receptor that recognizes (i.e.,

-76-

binds to) IE<sup>k</sup> with bound MCC 91-103 peptide. Lymph node cells were isolated from the resulting progeny. The isolated lymph node cells were then stained with fluorescein-labelled antibodies specific the V $\alpha$ 11 (V $\alpha$ 11) or V $\beta$ 3 (V $\beta$ 3) chains of the transgenic T cell receptor specific for IE<sup>k</sup> with bound MCC 91-103 peptide, or antibodies specific for the transgenic IE<sup>k</sup>-MCC protein, and analyzed by FACS.

The results are shown in Fig. 12 and indicate that populations of lymph node cells isolated from the double transgenic mice had fewer numbers of T cells in their lymph nodes than populations of lymph node cells isolated from single transgenic mice expressing only the T cell receptor specific for IE<sup>k</sup> with bound MCC 91-103 peptide. In addition, lymph node cell populations isolated from the double transgenic mice contained fewer cells expressing the T cell receptor specific for IE<sup>k</sup> with bound MCC 91-103 peptide. Thus, the presence of the transgenic IE<sup>k</sup>-MCC protein reduces the total number of T cells, as well as, the number of IE<sup>k</sup> with bound MCC 91-103 peptide specific T cell receptor positive T cells in the lymph node populations of mice.

#### Example 5

This example demonstrates that IE<sup>k</sup> protein covalently attached to MCC 91-103 induces tolerance to IE<sup>k</sup> with bound MCC 91-103 peptide in mice.

-77-

Transgenic progeny expressing transgenic IE<sup>k</sup>-MCC protein were crossed with a strain of mice expressing IE<sup>k</sup> and IE<sup>s</sup>. Non-transgenic IE<sup>s</sup> mice, when primed with MCC 91-103 peptide, produce T cells that can respond to the MCC 91-103 peptide bound to IE<sup>k</sup>, as well as, the same peptide bound to IE<sup>s</sup>. Such T cells, however, comprise two different sets of T cells. IE<sup>k</sup>/IE<sup>s</sup> (kxs) mice and IE<sup>k</sup>/IE<sup>s</sup> (kxs) mice transgenic for IE<sup>k</sup>-MCC were primed with MCC 91-103 peptide, or a positive control hemoglobin 64-76 peptide (Hbβd) that can also be recognized by T cells in the presence of either IE<sup>k</sup> or IE<sup>s</sup>. T cells were isolated from the primed mice and assayed for their ability to respond to MCC 88-104 peptide or Hbβd 64-76 peptide plus IE<sup>k</sup> or IE<sup>s</sup> using methods described in Example 1.

The results are shown in Fig. 13 and indicate that T cells isolated from mice expressing the transgenic IE<sup>k</sup>-MCC protein responded well to the Hbβd 64-76 peptide plus IE<sup>k</sup> or IE<sup>s</sup>. The T cells also responded well to the MCC 88-104 plus IE<sup>s</sup>. When, however, the response of T cells isolated from mice expressing the transgenic IE<sup>k</sup>-MCC protein to MCC 88-104 IE<sup>k</sup> was compared with the response of T cells isolated from normal kxs mice, the transgenic T cells responded poorly. Thus, the results indicate that the transgenic IE<sup>k</sup>-MCC protein induced tolerance in the IE<sup>k</sup>-MCC transgenic mice.

While various embodiments of the present invention have been described in detail, it is apparent that modifications and adaptations of those embodiments will

-78-

occur to those skilled in the art. It is to be expressly understood, however, that such modifications and adaptations are within the scope of the present invention, as set forth in the following claims.



-79-

What is claimed is:

1. A Peptide-L-MHC molecule comprising an antigenic peptide, a linker and an MHC segment, wherein said peptide is linked to said MHC segment by said linker.
2. The Peptide-L-MHC molecule of Claim 1, wherein said MHC segment comprises at least a portion of an MHC class II protein.
3. The Peptide-L-MHC molecule of Claim 1, wherein said peptide is capable of binding to a peptide binding site of an MHC protein.
4. A formulation capable of inducing T cell tolerance comprising a composition selected from the group consisting of a Peptide-L-MHC <sub>$\alpha+\beta 2m$</sub>  composition and a Peptide-L-MHC <sub>$\alpha+\beta$</sub>  composition having an antigenic peptide joined by a linker to an MHC segment, said composition being anchored to the plasma membrane of a cell essentially incapable of stimulating a T cell response.
5. The formulation of Claim 4, wherein said cell is selected from the group consisting of red blood cells, fibroblasts, pluripotent progenitor cells, epithelial cells and neural cells.
6. A nucleic acid molecule having a sequence encoding a Peptide-L-MHC molecule comprising an antigenic peptide joined by a linker to an MHC segment.
7. The nucleic acid molecule of Claim 6, wherein said MHC segment is encoded by at least a portion of an MHC class II  $\beta$  chain gene.

-80-

8. A recombinant cell having a recombinant molecule comprising a nucleic acid molecule operatively linked to an expression vector, said nucleic acid molecule encoding an antigenic peptide joined by a linker to an MHC segment.

9. The cell of Claim 8, wherein said cell produces a Peptide-L-MHC molecule.

10. A pharmaceutical reagent comprising a compound selected from the group consisting of a Peptide-L-MHC molecule having an antigenic peptide joined by a linker to an MHC segment and a recombinant molecule encoding a Peptide-L-MHC molecule having an antigenic peptide joined by a linker to an MHC segment.

11. A method to regulate an immune response, comprising administering to an animal an effective amount of a pharmaceutical reagent comprising a compound selected from the group consisting of a Peptide-L-MHC molecule having an antigenic peptide joined by a linker to an MHC segment and a recombinant molecule encoding a Peptide-L-MHC molecule having an antigenic peptide joined by a linker to an MHC segment.

12. The method of Claim 11, wherein said pharmaceutical reagent further comprises a pharmaceutically acceptable carrier.

13. The method of Claim 11, wherein said method comprises delivering said recombinant molecule in such a manner that the protein encoded by said recombinant molecule is expressed on the surface of cells selected from

-81-

the group consisting of red blood cells, antigen presenting cells, fibroblasts, pluripotent progenitor cells, epithelial cells and neural cells.

14. The method of Claim 13, wherein said cells comprise red blood cells.

15. The method of Claim 11, wherein said animal is tolerized by said pharmaceutical reagent.

1/13




Fig. 1

2/13




Fig. 2

3/13




Fig. 3

4/13




Fig. 4




Fig. 5



6/13




Fig. 6

7/13




Fig. 7

8/13




Fig. 8

9/13




Fig. 9

10/13




FIG. 10

11/13




FIG. 11

12/13




FIG. 12

13/13




FIG. 13



## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US95/02689

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :C07K 19/00; A61K 35/12, 35/18, 39/00, 39/385; C12N 15/62, 5/10

US CL :530/350, 403; 424/192.1, 93.21; 536/23.4; 435/240.2

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 530/350, 403; 424/192.1, 93.21; 536/23.4; 435/240.2

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

U.S. Automated Patent Search, World Patents Index, Medline. Keywords: MHC, fusion, chimera?, chimera?, conjugat?, biomembrane#, red blood cell#, rbc.

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US, A, 5,242,687 (TYKOCINSKI ET AL) 07 September 1993, see column 2, lines 39-50; column 6, lines 21-43; column 11, line 59 to column 12, line 59; column 13, line 61 to column 14, line 7; and column 17, lines 27-39.	1-15

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A* document defining the general state of the art which is not considered to be of particular relevance	*X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*E* earlier document published on or after the international filing date	*Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z*	document member of the same patent family
*O* document referring to an oral disclosure, use, exhibition or other means		
*P* document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

05 JUNE 1995

Date of mailing of the international search report

13 JUN 1995

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

MARY E. MOSHER

Telephone No. (703) 308-0196